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The aim of this thesis was to construct a theoretical framework for strategic brand man- 
agement of health ingredient brands in international context. The purpose of this thesis 
was to provide insights to strategic brand management in field of health ingredients, and 
help the commissioner and other companies in the business sector in drafting brand strat- 
egies in varying organizational and international contexts, managing their ingredient and 
corporate brands, building brand equity, and protecting their intellectual property. The 
main outcome of this thesis was a brand management strategy for the commissioner. 
 
The theoretical framework for the thesis was gathered through exploratory literature re- 
view. Further analysis was conducted by synthesizing general theory and industry-spe- 
cific data. The theoretical section explores theory of Ingredient Branding, Corporate 
branding, branding in business-to-business context and their international implications. 
The empirical part consists of analysis of in-depth interviews conducted among commis- 
sioners’ clients and situational analysis. The data was collected from eight cosmetic and 
food manufacturers. Evaluation of different strategic options was based on theoretical 
framework, empirical findings, and situational analysis. Brand management strategy was 
drafted based on the analysis. 
 
In international context, companies need to choose whether to drive global convergence 
or local divergence in terms of their brand strategies. Brand policies and strategies should 
be aligned with organizational structure and overall business and corporate strategies. 
Strategies should promote integrity and consistency of brands, especially in Business-to- 
Business sector, which emphasizes relationships and corporate brands. Empirical finding 
supported idea of corporate brands at the core of commissioners’ brand management strat- 
egy.  In SMEs, limited resources restrain execution of multilevel branding strategies, but 
findings indicate SMEs can clearly benefit from strategic brand management and use 
brands to build sustainable competitive advantage in international markets. 
 
Key words: strategic brand management, business-to-business branding, ingredient 
branding, bio-branding, corporate branding, branding health ingredients, ingredient 
brands, branding, brand management, strategy 
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MNE Multinational Enterprise  
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RBV  Resource-based view 
R&D  Research & Development 
SMEs  Small- and medium sized Enterprises 
USP  Unique selling point 
eWOM Electronic word of mouth 
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1 INTRODUCTION 
 
1.1. Context 
 
Health is a growing global concern. While quality of care and life expectancy are increas-
ing in developed societies, at the same time population is aging and suffering from dis-
eases associated with modern life-style. Informed consumers are increasingly interested 
in focusing on self-care and prevention, and together with favourable demographics as 
well as regulatory and economic development, health has grown to one of the megatrends 
of the 21st century (Blackett & Robins 2001). Strong development and growth has been 
observed during the past decade across the all categories in consumer health sector (Eu-
romonitor 2014), creating a strong pull for products and innovations in health and nutri-
tion. 
 
Biotechnology inventions and products are changing the paradigms of healthcare and nu-
trition. The European Commission has classified biotechnology as one of the Key Ena-
bling Technologies (KETs), which “provide the basis for innovation in a range of prod-
ucts across all industrial sectors, underpin the shift to a greener economy, are instrumen-
tal in modernising Europe’s industrial base, and drive the development of entirely new 
industries”.  Demand for biotechnological and medical innovations has grown rapidly, 
and ingredient manufacturers must constantly develop novel products to meet the require-
ments of growing and developing markets (Friedman 2014). Strong growth has been seen 
in B2B health ingredient markets across all the market sectors. Former niche-product have 
been adopted by big players, and as markets are maturing, competitive rivalry is intensi-
fying, and the competitive landscape is changing rapidly.  
 
Compared to many other industries, biotechnology and pharma sectors have been lagging 
behind in marketing (Friedman 2014; Blackett & Robins 2001). The traditional B2B 
brand strategy has targeted the marketing activities only towards the next link in the value 
chain. Several successful ingredient brands have demonstrated the potential of ingredient 
branding for both the ingredient creator and for the manufacturer of finished goods (Ko-
tler & Pfoertsch 2010). The durability of brands compared to technological assets the 
industry leans on, such as patents which expire within a decade, makes branding an inter-
esting and highly strategic tool when companies are pursuing sustainable competitive ad-
vantage (Blackett & Robins 2001). Production and R&D costs in Europe are high, and 
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European Ingredient manufacturers need to adjust to changing market conditions by in-
creasingly differentiating from competitors. The field in Finland is fragmented and most 
of the companies are SMEs, which often lack strategic resources and competences for 
effective internationalisation and international marketing.  
 
Health ingredient is an industry term, and unlike APIs (Active Pharmaceutical Ingredi-
ents) they lack official and legal definition. Ingredients referred as health ingredients are 
active ingredients which are somehow beneficial for human health or contribute to well-
being. This category covers wide range of ingredients, which are used in wide range of 
product applications. Health ingredients as term covers natural ingredients, functional 
foods, sports nutrition, active food ingredients and active cosmetic ingredients. While 
ingredients classified as health ingredients and their applications may be divergent and 
field very heterogenous, these products share common industry platforms and marketing 
systematics, and fall under same regulations.  
 
1.2. Commissioner of the thesis 
 
The commissioner of this thesis is Fingredient Oy/Ltd, a health ingredients supplier and 
R&D service provider based in Tampere, Finland. Commissioner is focused on Finnish 
biomaterials in health applications and manufactures health ingredients for domestic and 
international distribution for food, cosmetic and pharmaceutical sectors. The commis-
sioner is applying for growth funding for term 2018-2019, the initial project involves 
350 000 € of total funding for new investments and internationalisation (processing unit, 
machinery, product development, international channel development). The outcome of 
this thesis, a brand management strategy, aims at supporting this project and the growth 
targets (100 000 € turnover increase in short-term, at least one new full-time position 
created in terms of work force, doubling the turnover in medium term).  
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1.3. Thesis purpose and objectives 
 
The aim of this thesis was to construct a theoretical framework for strategic brand man-
agement of health ingredient brands in international context. The constructed brand strat-
egy framework should be applicable in international markets, provide instrumental value 
for operators in the industry, and provide a brand strategy framework applicable for var-
ious products used in variety of health applications. The main outcome is a brand man-
agement strategy for the commissioner, which is constructed by applying empirical find-
ings and theoretical framework of strategic brand management. The thesis outcome 
should support the business growth objectives defined in the introduction of this thesis.  
 
The purpose of this thesis is to provide insights to strategic brand management in field of 
biotechnology and health ingredients and help commissioner and other companies in the 
business sector drafting brand strategies in varying organizational and international con-
texts, managing their ingredient and corporate brands, building brand equity, and protect-
ing their intellectual property. The purpose is to provide information about strategic brand 
management especially for small and medium-sized (SMEs) companies in the field, help 
companies to allocate their limited marketing resources in optimal way, and improve 
competitiveness of their product offerings in global health ingredient markets. SMEs, 
such as the commissioner of this thesis, constitute a significant part of biotechnology 
sector in Finland, 40% of all R&D expenses in 2015 cumulated by companies with under 
50 employees (Statistics Finland). The sector has been lagging behind in terms of mar-
keting and branding. Strategic brand management could help SMEs capture markets 
shares on growing global markets.   
 
 
1.4. Main research questions 
 
The main research questions:  How strategic brand management can be utilized by the 
commissioner and other companies in health ingredient sector? How are these brands 
developed, managed, and monitored?  
 
Sub-questions: 
What is the role of branding in B2B health ingredient sector? 
How corporate and ingredient brands are interconnected? 
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What branding strategies health ingredient manufacturers can use? 
What type of branding strategies have succeeded in global B2B arena? 
What industry-specific factors affect brands and branding? 
 
What are core values, potential unique selling points, and other attributes that form com-
missioners brand? 
What kind of branding strategy could benefit the commissioner?  
 
 
1.5.  Thesis structure 
 
1. Theoretical framework 
Theoretical framework consists of two main outlines:  First part of the thesis contains 
general brand management theory obtained through literature review. The second 
part consists of the theoretical framework of branding in business-to-business con-
text, in international context, and finally in the context of the business sector.  
 
2. In-depth interview results and summary  
In-depth interviews were used for mapping positioning and attributes which form 
unique value proposition.  This part contains the summary and analysis of collected 
data and provides supplementary and supportive data for branding strategy. 
 
3. Situational analysis and evaluation of different strategic options 
This part describes microenvironmental and macroenvironmental analysis describing 
implications that may affect branding strategy and aims at providing compressed sit-
uational analysis. It renders the current situation of the company and its operational 
environment by describing current marketing strategy and goals, and through SWOT 
and PESTEL-analyses. Strategic options based on theoretical framework are pre-
sented and analysed according to predefined methods obtained from the theory.  
 
4. Brand management strategy for the commissioner 
Final part and the outcome of this thesis is brand management strategy for the com-
missioner. This part is based upon theory, situational analysis, and empirical findings 
of branding research.  
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2 METHODOLOGY 
 
2.1. Desk research 
 
The first part of the thesis consists of theory of branding in B2B context, ingredient brand-
ing, corporate branding and theory of strategic brand management. The theoretical frame-
work for the thesis was gathered through exploratory literature review. Further analysis 
was conducted by synthesising general theory and industry-specific data. Relevant liter-
ature was searched mainly through databases of University of Salford and Tampere Uni-
versity of Applied Sciences. Material was supplemented with industry-specific articles 
and journals (Nature Biotechnology, News Medical, Nutraingredients), and commercial 
market research (Euromonitor, Mintel, Innova Insights, Marketsandmarkets). Theoretical 
basis was composed by systematic research of literature mentioning in the title, the key 
words or the abstract the words and phrases B2B branding, branding, strategic brand 
management, ingredient branding, corporate branding, brand management, intellectual 
property rights (IPRs) in biotechnology, intellectual property (IP), patents, and patenting 
biotechnology. Inclusion criteria included publication date (relatively recent data), and 
relevancy when screened against objectives, purpose and research questions of this thesis.  
 
While there is a relatively extensive existing body of literature of pharmaceutical brand-
ing, industry specific literature of branded ingredients not classified as APIs is lacking. 
Due to the similarities in marketing systematics between health ingredients and pharma-
ceutical ingredients, also noted in the literature, pharmaceutical industry is used as a ref-
erence in this thesis.  Health ingredients and pharmaceuticals represent similar benefits 
for the consumer (while health ingredients may be focused on prevention and pharma-
ceuticals on treatment, they may be targeted for exactly same health problem), they have 
similar short PLCs, and they are typified by high R&D costs, dependence on clinical 
research, highly regulated marketing macroenvironment, intensified competition, highly 
informed and active consumer base. Health ingredient sector often draws marketing and 
branding strategies from pharmaceutical sector, and these sectors often overlap. There-
fore, theoretical research of pharmaceutical industry was considered suitable reference 
point, despite partially different marketing systematics of these fields.  
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2.2. Empirical research 
 
Qualitative data collection methods were used to obtain data from existing clients. Clients 
were asked standardised open-ended questions, themes were further discussed in struc-
tures interviews, and answers were coded according to which brand building instrument 
they represented. Answers were further analysed in relation with different strategic op-
tions. The questions concerned B2B clients’ decision-making process and priorities post-
purchase, and reasons why clients chose to purchase from the commissioner.  Brand 
building instruments, presented in theoretical framework of these thesis were primary 
instruments: (1) Direct experiences (2) Marketing communications (3) Price (4) Distri-
bution. Secondary association related instruments that affect brand image were: (1) Co-
branding (2) Endorsers (Celebrities, opinion leaders) (3) Country-of-origin effects (4) 
Sponsorship. The aim was so gather clients’ opinions and feelings about different brand-
related aspects and understand them better from clients’ perspective. Whether clients fo-
cus was on individual products or the organisation as a whole was also a point of interest.  
Clients were also asked about the media channels they use for obtaining information about 
health ingredients, and their purchasing process. List of questions can be found in Appen-
dix 1.  
 
 Inclusion criterion was more than one purchase in past 6 months, interviews were con-
ducted in between November 2017 - January 2018. Clients were also asked about the 
media channels they use for obtaining information about health ingredients.   
 
Representatives (managerial level and involved in purchase process) of eight clients from 
Europe, Canada and Japan participated. Client agreed to publishing their statements, their 
industry sector and home country. Interviews were conducted one-to-one by email, 
phone, or face-to-face, depending on clients’ location. Questions used in in-depth inter-
views are presented in Appendix 1.  
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3 THE CONCEPT OF BRANDING 
 
3.1. Brands as strategic assets 
 
According to the American Marketing Associations definition, brand is a name, term, 
design, symbol, or any other feature that identifies one seller's good or service as distinct 
from those of other sellers, which close to a legal definition of brand, “a sign or set of 
signs certifying the origin of the product or service and differentiating it from the compe-
tition” (Kapferer 2008, 10). Keller & Kotler (2014) define brand as “… a set of mental 
associations, held by the customer, which add to the perceived value of a product or ser-
vice”, widely considered as a classical definition of brand in the branding literature. Kap-
ferer (2008) also defines a brand as “a summary of unique values and benefits” and states 
that “brand is a name that influences buyers”. In other words, brands are core values and 
benefits in concentrated, compressed form, clearly differentiated from competitors’ core 
values and benefits with unique set of signs, but most importantly, they are what consum-
ers think of them.  
 
Managerial strategic view is naturally focused on creating value with strategic brand man-
agement, and the main managerial level question, as well as one of the core research 
questions in this thesis, is how to create and build value with strategic brand management. 
Despite some accusations of branding being outdated and overused tool, it remains highly 
strategic issue in all sectors, since there are only relatively few strategies that can provide 
companies long-lasting competitive advantage (Kapferer 2008, 1-2.). Brands are condi-
tional assets, which means they must be aligned with what is tangible, but they have a 
potential to become distinctive and lasting strategic resources for a company. According 
to resource-based view (RVB) (Barney 1991), which argues that the strategic resources 
and capabilities are behind competitive advantage or disadvantage of a firm, distinctive 
strategic resources are the main reasons behind sustainable competitive advantage. To 
brand or not to brand is a first strategic question a company faces in terms of strategic 
brand management.  
 
Companies with strong brands can benefit from price premiums, lower price elasticity, 
advertising effectiveness, better acceptance of brand extensions, and they can often ex-
tend product lifecycles and enjoy higher customer loyalty (Worm 2011, 51). Building 
brand requires both strategic resources and strategic capabilities – Financial resources are 
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needed, but are ineffective without strategic thinking, creativity, and competence. Invest-
ments always involve risks. So-called no-branding brand strategy has emerged as an al-
ternative or an opposed strategic view. Not to brand is a perfectly valid strategic choice, 
but it needs to be justified one in an operating environment where brands have become 
threshold strategic assets. If a firm makes a conscious choice to go with a no-brand strat-
egy, then no-brand strategy must be connected or at the core of unique values and benefits 
associated with the product and the one that differentiates the unbranded product from its 
competitors, which is the case for example with branded versus generic medicine. After 
the brand revolution, brands have become a norm, and deeply integrated to our daily lives. 
In post brand revolution era, branding may seem an obvious choice. The core idea of this 
work is that companies should critically assess their environment and their internal re-
sources prior to deciding whether to brand or not, what to brand, and how to brand. 
 
 
3.2. Brand equity 
 
According to Interbrand Health Top 100 Pharma brand ranking in 2016 that quantifies 
the corporate brand’s contribution to business performance in the biopharma industry, top 
10 biopharma brands represent approximately USD $129 billion in brand value (Inter-
brandHealth 2016).  Brands are assets. While their value is difficult to measure, primary 
reason for their existence is their contribution to potential future profits. Value of a brand 
is measured as brand equity. Brand equity, added value that is generated through brand 
management process, consists, according to the consensus of current research literature, 
of interlinked dimensions of brand loyalty, brand awareness, brand associations (attribu-
tion), and perceived quality, as represented in Figure 1 (Aaker 2013).  
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FIGURE 1. The four dimensions of brand equity – Awareness, Attribution (Associations), 
Perceived Quality, and Loyalty. Adapted from Aaker (2013). 
 
High levels of positive brand equity result in customers willingness to pay brand pre-
mium, recommend the brand, and consider brand extensions, which in turn provides the 
brand owner opportunities in revenue generation and opportunities to improve overall 
performance (Biedenbach, Benston & Marell 2015). Consensus in between different 
brand equity models arises from an idea that the true value of a brand lies in the relation-
ship between the customer and the brand. This idea is expressed in Keller´s Customer-
based brand equity model (CBBE). Customer-based brand equity can be built and man-
aged through creation and administration of brand knowledge structures (Kotler & Keller 
2012, 142), which refer to brand equity dimensions mentioned above. Simon & Kotler 
(2003) have drafted a bio-brand equity model (Figure 2), in which the authors emphasize 
importance of brand loyalty, note that attribution needs to be salience, and in terms of 
quality, emphasize clinical performance. Simon & Kotler (2003, 131-132) also propose 
other important quality attributes, including corporate innovation, industry image, and 
corporate accountability. Figure 2 gives insights to the industry specific factors that affect 
brand equity, while bio-brands equity still essentially constitutes of the same elements as 
the equity of any brand – awareness, loyalty, salience, and judgement of the customers. 
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FIGURE 2. Bio-brand equity, adapted from Simon & Kotler (2003, 132), original version 
Simon /SDC Group, 2002.  
 
There are two main paradigms for measuring brand equity, or in other words, strength of 
a brand: Customer-based view and purely financial approach (Kapferer 2008). Above 
example of biopharma industry not only demonstrates financial potential of brands as 
strategic assets, but also represents brand equity in dollars or euros. However, these dol-
lars are generated through management of brand equity dimensions and customer 
knowledge structures. Brand equity may be somewhat complex concept and challenging 
to measure exactly, but there seems to be a strong consensus of one thing: Brands do have 
a real tangible effect on financial performance.  
 
 
3.3. Brand architecture  
 
The first part of strategic brand management process is whether to brand or not. If brand-
ing, based on careful consideration and assessment of company’s resources and operating 
environment, seems like a fitting option, a next strategic decision is what to brand. Brand 
architecture is a fundamental and highly strategic choice: “A coherent international 
brand architecture is a key component of a firm's overall marketing strategy as it provides 
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a structure to leverage strong brands into other markets, assimilate acquired brands, and 
rationalise the firm's branding strategy.” (Sanchez 2004). Aspirin® pain-killer is among 
the most recognised product brands of all time (Friedman 2014), but its manufacturers 
name (Bayer) is a well-known brand too. How are these brands interlinked? 
 
Brand architecture can be defined “as an integrated process of brand building through 
establishing brand relationships among branding options in the competitive environ-
ment” (Sanchez 2004). The brand architecture structures the relationships between the 
brands within and organisation, e.g. how the brands are related or interlinked to each 
other, and how they are differentiated from one another. Brand architecture is a highly 
strategic structure because it helps rationalising the whole branding strategy, assimilating 
acquired brands, and managing brand portfolio. Brand architecture focuses on examining 
relationships between corporate and different product or sub-brands and optimising them. 
The degree of synergy between the corporate brand and the product brand depends on the 
brand architecture: A strong corporate brand may help in leveraging multiple product 
brands (Muzellec & Lambkin 2009).  
 
Building brand architecture is an evolutionary process and the structures are shaped by 
competitive realities and past management decisions (Sanchez 2004). Muzellec & Lamb-
kin (2009) propose two alternative approaches for brand architecture strategies: An inte-
gration strategy (strategy towards branded house) which seeks to achieve image align-
ment between corporate and product brands, and a separation strategy (strategy towards 
house of brands) which seeks to create separated and differentiated brands that are inde-
pendent entities. Table 3 presents different strategic options for brand architecture as de-
scribed by Kapferer (2008). These strategic options are further examined in Table 4, 
where their advantages and disadvantages are summarised. Integration strategy creates 
coherence, while separation strategies allow freedom (Table 3).  
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TABLE 3. Brand architecture models, classified based on degree of coherence and brand-
ing level, Kapferer (2008)  
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Brand architec-
ture type 
Description Advantages and disad-
vantages 
Example  
One Branding Level 
PRODUCT 
BRANDS  
Company is not identified at 
all, or it is very discreet. Indi-
vidual products are branded.  
+ Enables differentiation  
+ Competition in same markets 
+ No negative spill-over 
- High costs 
- No positive spill-over effect 
Pycnogenol® 
NutraSweet® 
UMBRELLA 
BRAND 
Umbrella brand is sometimes 
called a family brand. Single 
brand name is used for several 
products. Umbrella is typically 
a line brand, containing sev-
eral complementary products. 
Products do not have their own 
brand names. 
+ Allow different strategies 
+ Positive spill-over within the line 
+ Exploitation of successful con-
cept 
+ Reduces launch costs 
- Lines have limits 
- Innovations may not reach full 
potential is added to existing 
line 
 
Aligning: Du Pond 
FloraFit® Probiot-
ics / GUARDIAN® 
Plant extracts (Hy-
brid). 
 
MASTER-
BRAND 
Corporate brand or corporate 
Masterbrand uses single brand 
for entire corporation and its 
product range.  
+ Strong spill-over effect 
+ Economic 
+ Reassurance, source effects 
- Requires scale 
- Requires coherency and simi-
larity (clear range) 
Sigma-Aldrich 
 
 
Two Branding Levels 
MAKER´S 
MARK 
Manufacturers mark works as a 
seal for a product. Corporate 
brand is not enhanced. Aimed at 
distributors. 
- Maker´s mark is not attached 
with values or identity, it works 
as an identification. 
Horsphag Research 
ENDORSING 
BRAND 
Corporate brand reputation 
stretched to wide range of prod-
ucts with individual product 
brand. 
+ Economic way to give company 
name and allow product a brand 
status 
- Little image transfer to the en-
dorser 
 
ICI 
Bayer 
Monsanto 
SOURCE 
BRAND 
Source brand strategy is like um-
brella strategy, but products 
have their own brand names. 
Two branding levels, strong cor-
porate brand and strong differen-
tiated product brands.  
+ Parent brand reassurance and 
values combined with differentia-
tion 
+ Parent brand strong incentive for 
purchase decision 
- Requires high coherency and 
consistency, a clear range of 
products 
DSM 
 
TABLE 4. Description or brand architecture types, advantages and disadvantages, and 
examples from the field, adapted from Kapferer (2008, 347-369). 
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Versatile brand architectures are present in the field, and both branded house (integration) 
and house of brand (separation) strategies are used. Big global suppliers, like Azelis, Du 
Pond (Danisco) (Figure 5) and DSM, typically go with integration strategy. Their brand 
portfolios contain ingredients for various segments. Integration strategy is also used by 
companies which have narrow or very integrated product brand portfolios, for example, 
UK-based Oat Cosmetics (Figure 5) has a clear corporate brand: The company is special-
ized in dermatological active ingredients derived from oat. As seen from the Figure 5, 
very different types of organisations from the field use integration strategy. It is important 
for companies to understand that there is not necessarily a one strategy that succeeds over 
another – It depends on the execution and the brand itself. In fact, diverse architecture 
types may work as differentiators: B2B client may purchase from a branded corporation 
it trusts (category-leading supplier) or choose a branded ingredient that is perceived some-
how superior (category-leading product).  
 
 
FIGURE 5. Different type of B2B heath ingredient companies that use integrated archi-
tecture.  
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GRAPH 6. Positioning alternative branding strategies (Kapferer 2008, p. 352) 
 
Key questions on brand architecture are how many branding levels there should be, how 
these levels should be linked, and what is the role or the corporate brand (Kapferer 2008, 
351-352). The choice should be based upon in where exactly the value is located (Kap-
ferer 2008). If a corporation has a single innovative bio-material, relatively obvious 
choice is to brand the product. If the corporation manufactures multiple ingredients, the 
choice becomes more difficult.  In the field of health ingredients two branding levels are 
very typical – Trusted manufacturer reduces risks related to the product. Risk manage-
ment has a central role in ingredient branding, yet ingredients still are highly differenti-
ated. The choice also depends on the degree of consistency in the product portfolio, es-
pecially in between an endorsing brand and a source brand. High degree of coherency 
favours umbrella brand, masterbrand, or source brand architecture types (Branded house). 
Urde (2003) emphasizes the importance of shared core values when following two-level 
branding strategy (Figure 7): Corporate brand creates credibility, while product brand is 
the differentiating factor and brings added value.  
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FIGURE 7. Shared core values between corporate and product brand. Adapted from Urde 
(2003).  
 
The brand architecture choice is naturally bound to strategic capabilities and resources of 
a company, since managing individual product brands along with corporate brand is very 
resource-intensive. However, it limits negative spill-over and thus reduces the risk asso-
ciated with new product launches: If new product flops, other product brands remain rel-
atively unaffected, whereas if the one product of a branded house is a failure, the reputa-
tion of the whole house suffers. Integration of brands is a safer choice also from financial 
perspective: If a new product fails, resources used for its marketing and branding are 
wasted, but if the failure brand capitalised mainly on corporate master brands reputation 
and financial resources were not used for its branding, the organisation suffers less finan-
cial damage. Organisation can start with one branding level and add another level later 
when it develops and grows. Brand architecture should be managed, and it is crucial to 
perceive brand architecture as a dynamic and evolving structure (Figure 8).  
 
Organisations should also consider their stakeholders when making decisions on brand 
architecture. According to Muzellecs & Lambkins (2009) dynamic model of brand archi-
tecture management, different levels interact with different stakeholders. Corporate brand 
is channelled towards suppliers, investors, general public, government, and shareholders, 
while product brands are targeted towards consumers. (Muzellec & Lambkin 2009). This 
model is typical for publicly traded companies.  
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FIGURE 3. Muzellec & Lambkin (2009) Relationship between brand architecture and 
stakeholders. 
 
23 
 
3.4. Brand identity 
 
When thinking of a brand, we often think about name or logo. The outward-focused ex-
pression of a brand – including its name, trademark, communications, and visual appear-
ance – form the brand identity, which attempts to physically capture the way the organi-
zation wants the customers to be perceive the brand. Brand image is often used as a syn-
onym for brand identity, but more holistic concept of brand identity was chosen for this 
work.  Kapferer (2008) has created a famous framework for analysing different aspects 
of the brand identity: The brand Identity Prism (Figure 9), which is used in the branding 
strategy framework of this thesis. There are several similar frameworks with some varia-
tions, but brand identity is typically seen as a representation of corporate culture and its 
relationships with different stakeholders, presented through physical attributes and brand 
personality.  
 
 
 
 
FIGURE 9. The Brand Identity Prism (Kapferer 2008). 
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3.4.1 Brand Physique 
According to brand identity prism, brand consist, first of all, of Brand physique repre-
sented through various brand elements, like logo, name, colours, packaging etc. In B2B, 
brand physique is often less about the product, which in health ingredient sector is typi-
cally liquid or powder, often with neutral colour and odour, and more about marketing 
communications and visuals. In component sector, the product itself may not be distinc-
tive itself. Logos and names are central parts in the bare and subtle world of Business-to-
Business brands. 
 
3.4.2 Brand personality 
Brand personality reaches beyond these tangible characteristics, which can be analysed 
with human personality traits, one of the frameworks for this analysis being Aakers Brand 
Personality Dimensions (1997). In Business-to-Business markets personalities are per-
haps more discreet, but they exist nevertheless, and there are brand personality differ-
ences, especially in terms of SMEs which may be focused on certain niche segments and 
have created brand personalities that work for their customers. There are companies who 
are innovation and technology driven (excitement, sophistication), while others may be 
looking for greener options (caring, sincere brands like Indena, AOM). Some nutraceuti-
cal companies imitate pharmaceutical sector and create brand personalities that signal 
competence (Azelis, BASF), while for example manufacturers specialized in cosmetic 
and dermal ingredients may come out as luxurious and feminine. Clear brand personality 
that is aligned with corporate values creates coherence. 
 
 
3.4.3 Brand culture 
In health ingredient sector, mainly functional values have been emphasized, particularly 
efficacy, safety convenience and cost-effectiveness. This doesn´t mean that technologi-
cally oriented field doesn´t have a culture. Nestlé, a former food ingredient supplier 
though nowadays more focused towards consumer segment, for example, struggles to 
convey messages of fun and energetic products because of what Kapferer describes as a 
puritan brand culture (Kapferer 2008).  
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3.4.4 Brand Relationship  
Kapferer (2008, 185) describes brands as crux of transactions between people. Relation-
ship, which describe the mode of conduct as Kapferer states, is especially crucial for ser-
vice brands. In Business-to-Business, the focus is often on durability, trust, co-operation, 
timeliness and convenience (Worm 2009). Relationships are important, because many 
B2B manufacturers offer R&D services or contract manufacturing, and in a complex field 
services and co-operation is needed when incorporating ingredients into the end products.  
 
3.4.5 Reflection 
According to Kapferer (2008), brands are customer reflection: How she or he sees himself 
as a user of the brand. Reflection is how customers wishes to be seen as a result of using 
the product. In terms of health ingredients, this may mean being fitter, slimmer, having 
healthier skin or hair, being more energetic, more focused, happier, stronger, more agile, 
or just overall feeling better. It may mean being free of a certain condition. It is crucial 
that the brand enhances and encourages right kind of reflections. In B2B the question is 
does the brand need to resonate both for business client and the end-user of a finished 
product, and how another corporation reflects itself as a buyer of certain ingredient or 
component. Is the client organisation perhaps quality-conscious high-end corporation, 
when it buys certain ingredient from a certain manufacturer, or perhaps ethically con-
scious and down-to-earth?  
 
3.4.6 Self-image 
In general, people buying over-the-counter and preventive health ingredients and func-
tional foods may identify as, for example, fit, healthy, responsible patients who are taking 
care of themselves, or as individuals who value wellbeing, a reflection which is enhanced 
through lifestyle media and public advocates of preventive health care. Younger consum-
ers may seek optimal performance and reflect this through their consumption of health 
products and services. Brands must be able to support a positive self-image, even on in-
dividuals suffering health problems.   
 
 
 
 
26 
 
4 STRATEGIC BRAND MANAGEMENT PROCESS  
 
Strategic brand management is used to build, measure, and manage brands to optimize 
their value (Kotler & Keller 2012, 140). The aim is to create brand equity (Kotler & Keller 
2012, 140). The process outline, according to Kotler & Keller (2012), includes: 
 
(1) Establishing brand positioning 
(2) Planning and implementing brand marketing  
(3) Growing and sustaining brand value 
 
The essence of the branding process is creating differences – whether they are functional, 
rational, tangible, emotional or symbolic (Kotler & Keller 2007, 136). Keller, in his ear-
lier works suggest CBBE approach (Customer-based brand equity) to brand management, 
customer-based brand equity defined as the differential effect that brand knowledge has 
on consumer response to the marketing of the brand (Kotler & Keller 2007, 137). The 
approach was discussed already when introducing the concept of brand equity. Kotler and 
Keller (2007, 137) emphasize that in order to generate customer-based brand equity, con-
sumers must not think that all brands in the category are the same – In order to build 
CBBE, consumers need to acknowledge that there are meaningful differences between 
the brands. While these differences are often natural for innovative biotech products, in 
more crowded ingredient categories they can be built through e.g. sustainable or ethical 
sourcing of raw material, certifications or accreditations, patented or trademarked pro-
cesses, services, co-branding or corporate branding.  
 
Rosenbaum-Elliott, Percy, & Pervan (2011) use classical model of consumer decision 
making process with behaviouristic and socio-cultural theories that suggest distinctive 
brand management strategies for high- and low-involvement brands.  Whether the brand 
is low-involvement or high-involvement (symbolic) is characterised by price, frequency 
of purchase, symbolic meaning, social visibility, time commitment, potential for harm, 
and technical complexity axis. The more involvement the greater potential for building 
brand loyalty. In B2B context of health ingredients, this typically translates to brand man-
agement according to the principles of high-involvement.  
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4.1. Establishing brand positioning  
 
Kapferer (2008, 176) describes positioning as a two-staged process: 
 
1. Selection of competitive set against which brand is compared. 
2. Indication of difference or raison d´étre in comparison to other brands. 
 
As discussed already, brands are core values and benefits in concentrated, compressed 
form, clearly differentiated from competitors’ core values and benefits with unique set of 
signs. The first part is to identify what are the core values and benefits, and then find out 
what makes them different of competitors’ values. In health ingredient sector, position is 
one of the core strategy choices. Ingredients may have potential applications in variety of 
sectors, which makes the analysis more complicated.   
 
Phases for brand positioning according to Kapferer (2008): 
1. The evaluation phase – Identifying all unique aspects of the brand 
2. The exploration phase – Building scenarios: Is there global potential? Where 
would the potential buyers be?  
3. The test phase – Elimination and then further refining scenarios 
4. The strategic evaluation – Economic evaluation and comparison of scenarios 
against market forecasts 
5. Implementation and activation – The platform, marketing and launch 
 
Unique aspects for the evaluation phase could be, for example, origin of the material, 
locality, sustainability, innovative process, chemical profile, less side-effects compared 
to synthetic medicine, bioavailability etc. In the next phase, position scenarios for differ-
ent sectors can be created: What is the return of investment if the brand is taken into a 
sector with higher regulation? What are the other solutions to same health issue, and how 
the brand relates to them? Which markets the brand could thrive? Kapferer (2008) sug-
gests supportive questions for managers for positioning mapping (Table 10).  
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POSITIONING: Supportive questions for managers  
1. Compatibility Are the product´s current looks and ingredients compatible 
with this positioning? 
2. Consumer motivation How strong is the assumed consumer motivation behind 
this positioning? 
3. Market size What size of the markets are involved? 
4. Credibility Is this positioning credible? 
5. Competitive aspects Does it capitalise on a competitor´s actual or latent dura-
ble weaknesses? 
6. Financial resources  What financial means are required by such a positioning? 
7. Distinctiveness Is this positioning specific and distinctive? 
8. Sustainable competitive ad-
vantage 
Is this a sustainable positioning which cannot be imitated 
by the competitors? 
9. Possibility of exit in case of fail-
ure  
Does this positioning leave any possibility for alternative 
solution in case of failure? 
10. Price premium  Does this positioning justify premium price? 
11. Growth potential  Is there growth potential under this positioning? 
 
TABLE 10. How to evaluate and choose brand positioning according to Kapferer (2008) 
 
 
4.2. Planning and establishing marketing 
 
 
4.2.1 Formation of brand identity  
 
Brand identity was already described above in detail. In brand management process, 
brand identity works as the genetic code of the brand, and guides everyone involved in 
the process by answering the question “what the brand should be like” (Kapferer 2008). 
As Worm (2009, 46) states, there needs to be consistency in brand actions both over time 
and across the instruments of marketing mix. Brand identity is a very natural thing and 
begins from within the organisation. Halttu, Tähtinen & Juntunen (2009) note that in the 
beginning of SMEs organisational development, the owners and managers have huge in-
fluence and very often direct impact on core values, and therefore to the brand identity. 
Identity is often build on these constituents, and because it stretches to everything the 
organisation (or the product) is and does, it is challenging to manage. Worm (2009) and 
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Halttu, Tähtinen & Juntunen (2009) all emphasise the importance consistency over eve-
rything. Identity needs to be clearly defined and everyone within the organisation needs 
to have a clear idea what brand identity is to have a consistent outward expression of the 
brand. Corporate brand identity is formed by corporate culture, corporate behaviour, cor-
porate internal communications and corporate design (Halttu, Tähtinen & Juntunen, 
2009).  
 
 
4.2.2 Selection of brand elements 
 
Worm (2009, 45) suggest the following selection criteria for the brand elements: 
1. Conveyance of brands benefits and support to desired brand image 
2. Memorability, recognisability, and ease of pronunciation 
3. Likeability, aesthetics 
4. Transferability to brand extensions 
5. Legal protectability 
 
At the core of the brand identity is the brand name, with the brand mark or logo. Brand 
name can be either descriptive, associative (evocative) or free-standing (initialism like 
biotechnology MNE´s DSM or BASF, neologism, and combinations). A typical and sim-
ilar feature for APIs and health ingredients in general is using both generic, descriptive 
name (commonly used in scientific publications) and the brand name, (which may be 
descriptive, associative or free standing), as Shuiling & Moss (2004) suggest. According 
to Schuiling and Moss (2004), while the pharmaceuticals with descriptive names there is 
a big risk of creating a generic association that will benefit the development of generics 
and make the brand name more difficult to protect legally (Schuiling & Moss 2004). 
 
Visual symbols and logotypes are equally important and help in differentiating the brand. 
Looking at some of the well-known biopharmaceutical, food ingredient and biotechnol-
ogy companies, visuals are dominated with texts, and neutral colours, as the Figure 11. 
demonstrates.  
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FIGURE 11. Brand elements of biopharma and bio-brands 
 
 
4.2.3 Designing brand communications 
 
As Kapferer (2008, 156) states, brand needs to create 360° experience. Brand communi-
cation is the tool that binds the gap between brand identity and brand image. Brand iden-
tity guides how the brand communicates, and brand elements provide a frame for the 
communications, the symbols and the visuals used in the brand communications (Kap-
ferer, 2008, 156.). Employees are important link between the corporate identity and the 
corporate image (Halttu, Tähtinen & Juntunen 2009, 94), so brand communication plan-
ning should not only be focused on external, formal and structured communication. Brand 
communications is the unifying activity between all the other brand building activities 
(Halttu, Tähtinen & Juntunen 2009, 94), and both internal and external communications 
are needed.  
 
IMC or integrated marketing communications is often referred as main strategic approach 
when planning brand communication mix. IMC relates to how a brand transmits a clear 
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consistent message to its stakeholders.  The American Association of Advertising Agen-
cies published the first definition of IMC, as follows: 
 
"(IMC)… recognizes the value of a comprehensive plan that evaluates the strategic roles 
of a variety of communication disciplines advertising, public relations, personal selling, 
and sales promotion and combines them to provide clarity, consistency, and maximum 
communication impact." (American Association of Advertising Agencies, AAAA) 
 
More recent definitions by Percy (2008) describes IMC as follows: “IMC is the planning 
and execution of all types of advertising-like and promotion-like messages selected for a 
brand, service, or company, in order to meet a common set of communication objectives, 
or more particularly, to support a single positioning’” (Percy 2008).  
 
Companies have myriad brand communication channels to choose from. New concepts 
that are relevant for business-to-business brands are emerging, such as electronic word-
of mouth (eWOM) and consumer's online brand-related activities (COBRA). The IMC, 
when introduced, was seen to consist of advertising, sales promotions, personal selling, 
and public relations, but nowadays it is even more relevant with diverse online based 
channels being available. Touchpoints, connections between the organization and the au-
diences, express and promote the UVP (unique value proposition) of the brand, and each 
touchpoint needs to convey consistent brand message, each message reinforcing each 
other. There are several tools for optimising and analysing touchpoints that help in IMC 
planning, like service blueprints or customer journey matrices, but the core objective for 
strategic brand communications management is to identify the touchpoints and drive con-
sistency over them. One model designed by Spengler, Wirth & Sigrist (2010) for B2B 
companies displayed in Figure 12.  
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FIGURE 12. 360° Touchpoint Management adapted from Spengler, Wirth & Sigrist 
(2010). 
 
Spengler, Wirth & Sigrist (2010) have also drafted managerial checklist for optimal mar-
keting strategy mix, including following supportive questions for B2B companies:  
 
1. From the client perspective, which are the 30 most relevant contacts with the com-
pany or brand? 
2. Which ten new types of contact points will be relevant for the company over the 
next two years? 
3. Which activities should be re-examined, due to having insufficient breadth and 
depth of impact? 
4. Which key contact points need targeted optimisation? 
5. Which investments in which activities promise an optimal return on investment? 
6. Which combination of activities has the greatest potential for successful market-
ing and brand management? 
7. Which contact points can address and win new customers? 
8. Which contact points are most effective at retaining customers? 
9. Which contact points strengthen the brand-typical customer experience? 
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Arruda (2009) has suggested “the Three Cs” as a basic underlining criterion when design-
ing brand communications. The three Cs of Brand communication are clarity, consistency 
and constancy. Clarity means that brand message is clear, it is authentic, and is not too 
complicated. Consistency means driving coherence and uniformity across communica-
tion channels, stakeholders, and all brand communications. Constancy means exposure: 
Same uniform brand messages are constantly repeated. When brand identity and set of 
values attached to it are clear, and brand elements frame communications, communication 
strategy can mainly focus on channels, style, and whether brand is promoted inde-
pendently or whether brand messages are conveyed through product campaigns (Kap-
ferer, 2008, 210-211).  
 
 
4.2.4 Brand-building programmes 
 
Different brand building programmes can be drafted by creating a brand and unique mar-
keting mix and using combination of different brand building instruments, presented by 
Worm (2009), below:  
 
Marketing mix instruments that affect brand image (Worm 2009, 46-47) 
(1) Direct experiences 
(2) Marketing communications 
(3) Price 
(4) Distribution 
 
Secondary association related instruments that affect brand image (Worm 2009, 47) 
(1) Co-branding 
(2) Endorsers (Celebrities, opinion leaders) 
(3) Country-of-origin effects 
(4) Sponsorship 
 
The aim is to shape brand image and identity and affect how clients perceive the brand. 
Quality assurance can come from secondary associations, which organisations can utilise 
as branding instruments.  
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5 THEORETICAL FRAMEWORK OF INGREDIENT BRANDING 
 
5.1. The concept of Ingredient Branding 
 
Ingredient branding means creating a brand for ingredient or component, usually to pro-
ject high quality or performance of the ingredient or component to enhance brand percep-
tion of the host product. In other words, Ingredient Branding is marking or labelling the 
component or other industrial goods (Kotler & Pfoertsch 2010, 16.). As a theoretical 
model Ingredient Branding or InBranding is relatively new. Ingredient Branding has only 
started to thrive since the late 1980s as an accepted marketing concept, but since then 
Ingredient Branding has been exploited in variety of product applications in various in-
dustries and accepted as a part of strategic brand management of components, materials, 
parts and services, and manufactured, more sophisticated applications (Kotler & 
Pfoertsch 2010, 17). Some of the best-known examples of ingredient branding can be 
found from the field of information technology, but the concept has also been very suc-
cessfully utilized by food and nutraceutical industries.  
 
Ingredient branding is a concept often placed under the umbrella of co-branding or brand 
alliance, where two or more brands work together in alliance and create marketing syn-
ergy. The concept should be distinguished from corporate branding (branding an institu-
tion or the manufacturing company), discussed in detail below, even there is a possibility 
that these two approaches often overlap. A classic example of the interlacing of corporate 
branding and ingredient branding is NutraSweet Inc. with InBrand NutraSweet, an artifi-
cial sweetener (aspartame) which can be classified as one of the health ingredient (low-
calorie) success stories (Kotler & Pfoertsch 2010, 17.). Implications of ingredient brand-
ing are analysed in this thesis because in commissioners’ brand architecture product 
brands would be replaced by ingredient brands, but their management differs. 
 
 
5.2. Benefits and risks related to Ingredient Branding 
 
Ingredient brand should increase host brands brand equity, and ideally create a direct 
consumer pull for hosts offerings with the creators’ ingredients, which in turn helps to 
generate higher sales velocity, higher prices, greater loyalty, and greater propensity to 
advocate the product to others (Oliva et al. 2006). This includes brand equity effects for 
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both the user brands and the ingredient brand, according to the American Marketing As-
sociation Ingredient Branding Report (Oliva et al. 2006). In biopharma sector, where pa-
tenting often gains more attention than ingredient branding, a strong ingredient brand will 
benefit from high consumer loyalty and enable the brand therefore to be in a better posi-
tion and sustain sales after its patent expires (Schuiling & Moss 2004). Patent-centred 
industry has traditionally given patented products relatively short product life cycle (PLC) 
(In general patented novel health ingredients will go off-patent after an average of seven 
years from when they enter the market) which has inhibited biotechnology industry’s in-
terest towards investments in branding (Schuiling & Moss 2004). However, ingredient 
branding can extend PLC, which provides long-term profits, and ingredient branding can 
also help increase profits because differentiated branded offerings can leverage from price 
premiums.  
 
The benefits of the ingredient branding to the ingredient creator, according to Kotler & 
Pfoertsch (2010), include for example: 
1. Greater bargaining power over ingredient users and channel partners 
2. Clarity and control of communication of the customer benefits 
3. Downstream pull and higher prices 
 
The benefits of the ingredient branding to the host brand according to Kotler & Pfoertsch 
(2010): 
1. Management of risk related to ingredient purchase 
2. Endorsement of weaker host brand through branded ingredient 
 
 
 
 
5.3. Conditions for Ingredient Branding in product level 
 
There needs to be some basis for ingredient branding, and not all ingredient products are 
equally suitable candidates for implementation of ingredient branding strategy. Kotler & 
Pfoertsch have proposed different conditions required for Ingredient Branding in their 
book “Ingredient Branding: Making Invisible Visible” (2010): 
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1. Ingredient is highly differentiated 
2. The ingredient is central to the functional performance of the final product 
3. The final products are not well-branded themselves 
4. The final products are very complex  
 
Health ingredients are branded and are very potential targets for ingredient branding, 
since ingredients are typically highly differentiated, central or essential to the perfor-
mance of the final products, and products themselves may be complex. In order for an 
ingredient to become a brand, ingredient needs to be highly differentiated (Quelch 2007; 
Kotler & Pfoertsch 2010, 3.). Differentiation is the very core of branding, and one of the 
most crucial elements for the creation of a successful ingredient brand is being able to 
provide unique value proposition for all parties involved in the process (Oliva et al. 2006). 
This means, in practise, that ingredient is not only an enhancement, but has a major effect 
on the performance of the final product and expresses clear functional benefits. It is cru-
cial that the end-customer clearly understands the functions and benefits which the ingre-
dient or component provides (Kotler & Pfoertsch 2010). This means the organization 
must possess certain strategic capabilities. Especially in terms of medicinal products, the 
organizations must be able to convert scientific results and clinical research data into a 
form in which the end-consumers are able to clearly see the value of the ingredient brand.  
 
The most important functions brands provide are simplified decision making and reduc-
tion of risks (Kotler & Keller 2012, 140). Brand works as a symbol of confidence, a me-
dium for a guarantee between the consumer and the producer (Chevalier & Mazzalova 
2004). The aura of quality is the value that branded ingredients provide for their host 
brands. Pharmaceutical and nutraceutical industries are highly responsible for customer 
safety, so ingredient brands that succeed in communicating quality and cultivating confi-
dence among buyers are the brands that thrive in global B2B arena.  
 
5.4. Requirements for Ingredient Branding in Organizational Level 
 
Component or ingredient manufacturers operate in very different business environment 
compared to manufacturers of finished goods. Ingredient Branding strategy often requires 
an extensive reorganization of the present marketing strategy, as ingredient manufacturers 
often use single-level B2B marketing strategies that must be expanded into multi-stage 
marketing strategies in order to create successful Ingredient Brands (Kotler & Pfoertsch 
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2010, 36.). In Ingredient Branding, marketing activities are directed towards subsequent 
stages of the value chain leading up towards the end customers (Kotler & Pfoertsch 2010). 
In practice, the creator of the ingredient brand must have resources needed for active 
strategic brand management, as the ingredient creator often needs to take more control 
especially of the communication to end-user (Oliva et al. 2006). The ultimate objective 
of the ingredient branding efforts is to achieve a direct pull-effect from the end-consum-
ers. Ingredient Branding requires understanding of the value chain of the customer and 
knowing where the ingredient brand influences most.  End-user relations are especially 
challenging for biopharmaceutical and nutraceutical manufacturers, because DCT (Di-
rect-to-consumer-advertising) in the field is highly regulated.  
 
 
5.5. Health ingredient brands in international context 
 
While B2B context creates a different arena of branding compared to B2C, international 
context also requires strategic thinking in terms of branding. Divergent national contexts 
are a challenge for strategic brand management: Socio-economic differences, consumer 
behaviour and cultural interpretations of different component of brand identity may re-
quire high level of local adaptation of brand strategies. There is an on-going debate on to 
which extend MNEs can use global branding strategies (Schuiling & Moss 2004). Global 
branding involves offering a brand that has standardised a maximum number of elements 
of its strategy and marketing mix ideally to offer one standardised product to every inter-
national market (Schuiling & Moss 2004) According to Schuiling & Moss (2004), global 
strategy is gaining popularity due to the pharma sectors pressure to cut costs. Considering 
increasingly global trends in health, free flow of information and increasing health aware-
ness resulting to increasingly uniform consumer bases across geographical regions, and 
the administrative efficiency global brand strategy offers, it is an attractive option for 
companies that have enough strategic capabilities for the execution. In pharmaceutical 
sector there are well-known global brands, such as Viagra from Pfizer, Vioxx from MSD, 
Nexium from AstraZeneca and Keppra from UCB (Schuiling & Moss 2004), while global 
strategy can also be observed in health ingredient category. Sweetener brands like Nu-
traSweet® (sold in more than 100 countries) and stevia ingredients have been early 
adopters of global strategy (partly due to the co-branding efforts) – Their products are 
standardized and applicable for mass market, facing less regulation than targeted health 
solutions, which is why these products face minimal pressure for local adaptation. Some 
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natural ingredient manufacturers, despite nationally divergent regulatory systems and var-
ying customer needs and perceptions, have been able to use global strategy. Among them, 
for example Pycnogenol® has been able to execute global brand strategy due to relatively 
wide consumer base and number of applications of the product.   
 
However, even the mass-marketable health ingredients that address wide consumer or 
patient polls globally face widespread cultural variances (Simon & Kotler 2003, 150), 
and need to make trade-offs between driving global convergence or adapting to locally 
divergent cultural and regulative practices. In biopharma sector (APIs), the consensus of 
the best practise of international brand strategy among ingredient manufacturers is cen-
trally planned global brand position, while packaging, channels, media use, and even 
brand name may be locally varied (Simon & Kotler 2003). Manufacturers need to address 
different consumer knowledge levels and adapt their brand communications accordingly 
(Simon & Kotler 2003, 43). Simon & Kotler (2003) have proposed four different ap-
proaches for internationalisation of biopharma brands, the same applies of health ingre-
dients and APIs (Figure 13). Organisations can choose to drive global convergence 
(global reach and global integration strategies), or local divergence (local responsiveness 
and market focus strategies). In global reach, adaptation is minimal and single brand strat-
egy reaches over all market areas. Global integration adapts and creates consistent global 
strategy. Local responsiveness means the brand is always adapted to new markets, and 
that the brand may be represented in very different manner in foreign markets compared 
to domestic markets. Market focus aims at catering most promising geographic areas or 
clusters and adapting brand for these predefined markets (Simon & Kotler 2003). How 
centralised or globally convergent the brand and its dimensions are, depends upon the 
choice of market entry, and should be aligned with corporate structure and international 
strategy. In practise, SMEs often do not possess strategic capabilities for wide interna-
tional multilevel marketing campaigns, lacking both in financial resources and strategic 
competences international marketing.  
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FIGURE 13. Global Marketing Trade-Offs for Biopharma by Simon & Kotler (2003), 
SDS Group 
 
One of the factors to consider when taking brands to international level are country of 
origin effects. Several studies have investigated country of origin effects (COO) or prod-
uct country image (PCI), and their effect on consumer perceptions on the imported prod-
uct based on stereotypical image of the country where the product comes from. The COO 
effect is claimed to be stronger when the consumer has little or no knowledge of the 
brands from the exporting country (Melewar & Alwi 2015, 16). While the COO effect is 
not solely affecting consumer purchase behaviour, which in B2B arena is highly influ-
enced by e.g. channel, sellers’ technical skills, customer orientation, and innovation, ac-
cording to La, Patterson, & Styles (2009), COO will fundamentally influence brand im-
age, and therefore needs to be acknowledges when globalizing the brands.  
 
The commissioner and several other Scandinavian companies in same category utilize 
COO effect in their marketing and attempt to enhance it, in fact, the COO being among 
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leading marketing statements, by using “Arctic”, “Scandinavian” or “Nordic” COO mar-
keting claims to promote origin of the raw material of botanical and plant-based ingredi-
ents. Scandinavian and European nutraceuticals category benefit from favourable COO 
effects in B2B arena, according to Meštrović (2015): “New products from Europe are 
presumed to have passed stringent European development and quality requirements. As 
a result, European nutraceutical companies, which are generally considered leaders in 
innovation, enjoy a perception of producing the highest quality products”. European 
manufacturers can often benefit from “a negative home‐country bias” phenomenon, if 
the export destination (consumers home country) is less developed than the counterpart 
(in this case European manufacturer) who produces the same type of product, valid for 
example in Chinese markets (Wong Jeong, Stoel & Chung 2012). Favourable perceptions 
are also driven by innovation in food and health sector, and the fact that European legis-
lation is highly regulative for these sectors.  
 
5.6. Ingredient branding case: Pycnogenol®  
 
A case study from the field is used to illustrate the concept of Ingredient Branding. Pyc-
nogenol® is a brand name for natural health ingredient OPC (Oligomeric proanthocya-
nidins) derived from French Maritime Pine Bark and manufactured by Horphag Research. 
This natural ingredient contains procyanidins, bioflavonoids and organic acids, and func-
tions as an antioxidant and as an anti-inflammatory agent. Pycnogenol® also helps to 
generate collagen and hyaluronic acid, and aids in the production of endothelial nitric 
oxide which helps to dilate blood vessels. The multifunctional nature makes product mar-
ketable to wide customer bases. According to the Horphag Research, Pycnogenol® 
French maritime pine bark extract is available in more than 700 dietary supplements, 
multi-vitamins, cosmetics and health products worldwide, making it the key brand of the 
manufacturer. Horphag Research with Pycnogenol® was chosen in the same ingredient 
is manufactured by the commissioner, FLAVANTI® OPC Pine Bark Extract.  
 
The brand has developed own multi-level marketing concept that leans on brand commu-
nication. The R&D budget for the company in 2015, according to the CEO was over 1.7 
million euros.  Scientific evidence around the ingredient is exclusive and versatile: There 
are 340 published studies and 134 clinical trials conducted about safety, toxicity and clin-
ical efficiency of Pycnogenol®. This has helped the company to expand their customer 
base during and after the global roll-out, following optimisation strategy of biobranding 
41 
 
suggested by Simon & Kotler (2003) (the strategy is targeted mainly for APIs), which is 
presented in Figure 15. The strategy benchmarks from pharmaceutical sector and is ap-
plicable to health ingredients that are (or resemble closely) pharmaceuticals, as the case 
suggests. The company has its roots and legacy in pharmaceutical research, and therefore 
the ingredient, even not classified as API but a nutraceutical, follows a marketing strategy 
of biopharma sector, which has allowed development of a strong international ingredient 
brand.  
 
 
 
FIGURE 14.  Optimized biobranding, by Simon & Kotler (2003) 
 
The brand relays highly in integrated marketing communications (IMC) and multi-level 
communication strategy which uses high levels of content marketing. The core of Pycno-
genol® brand communication strategy is to ensure that scientific research related to the 
product is communicated to the end customers efficiently: Horphag Research CEO, Vic-
tor Ferrari, stated in NutraIngredients-USA interview that the aim is not to market for the 
consumers, but to educate them. In 2015 the company executed this strategy by publish-
ing a book “The Pycnogenol Phenomenon: The Most Unique & Versatile Health Supple-
ment”. The 196-page book written by Richard A. Passwater (PhD, a research biochemist 
also known for his role as a science editor for WholeFoods Magazine) and Peter 
42 
 
Rodhewald (Phd and a head of R&D in Horphag) contains combined study observations 
and anecdotal information, and is sold through Amazon, Adlibris and Walmart, along 
with number of other retailers. The book is targeted for retailers and end-consumers, and 
is part of multi-level marketing efforts that aim at creating a direct consumer pull. 
Horphag Research also utilizes variety of other communication methods, such as semi-
nars and social media advertisements, for transferring scientific messages to the end-con-
sumers. In 2015 the company launched a web campaign “Join the Conversation”, where 
recognized physicians and consumers discuss about their experiences with ingredient and 
products containing the ingredient.  While the communications follow multilevel strategy, 
the company behind the brand has done very little corporate branding – In practice, the 
ingredient only has one effective branding level. Instead of the corporate branding, the 
company uses, in a way typical for French wine makers as Kapferer (2008) stated in his 
work, other signs of quality instead of the corporate brand. In all the brand communica-
tions, even on scientific publications, “French Maritime Pine” origin statement is in-
cluded. Strong customer-based equity building model has enabled brands success story.  
  
What makes the case very interesting is that the similar materials are abundant in Finland. 
Finland as a country has a comparative advantage in biomasses derived from plant based 
sourced due to the strong forest industry, which is built on sustainable basis, and the fact 
that 80 % of the country is covered in forest. Despite the limited size, the country has 
strong knowledge-based economy, rich and clean raw material sources, and technologies 
and skills to exploit these resources. Creation and promotion of bioeconomy are part of 
public strategy. Universities and research institutes also play a significant role, and sev-
eral biotechnology enterprises have started as spin-offs from the different biomedical re-
search projects, such as Biotie Therapies Oyj (acquired by U.S based Acorda), Forendo 
Pharma Oy, Herantis Pharma Oy ja FIT Biotech. An example of novel biomass innovator 
is Montisera Ltd, which bought a patent from forestry giant UPM for extraction of bioac-
tive molecules from spruce (picea abies) that have potential pharmaceutical applications. 
Systematic strategic approach is needed if the commissioner and other Finnish SMEs aim 
at global arena.  
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6 THEORECTICAL FRAMEWORK OF CORPORATE BRANDING 
 
6.1. The concept of Corporate Branding 
 
Corporate brand and corporate branding are still emerging concepts in academic literature 
(Knox & Bickerton 2003). Hatch & Schultz (2003) have suggested seeing corporate 
branding as constituting of processes linking strategic vision, organizational culture and 
corporate images. Knox and Bickerton (2003) suggest definition of corporate brand as 
“the visual, verbal and behavioural expression of an organisation's unique business 
model”. Corporate branding reduces need of a firm to promote individual product brands 
(Hetrick & Martin 2006, 19). Biotechnology enterprises have not engaged in corporate 
branding efforts as widely as pharmaceutical sector, according to Simon & Kotler (2003), 
due to the smaller budgets but also due to the specialist audiences the products are tar-
geted. InterbrandHealths CEO Jane Parker commented the importance of corporate 
branding on the success of the top 10 ranked biopharma brands in 2016:“These 10 bio-
pharma brands are embracing a strategy that is somewhat new to the health and life sci-
ences sector: they are effectively leveraging their corporate brands and, in doing so, they 
are growing their businesses, fuelling innovation, and developing meaningful solutions 
for patients on a global scale.” (InterbrandHealth, 2016). Kay (2006) suggests that so-
cially responsible firms often create strong corporate brands. 
 
6.2. Benefits and risks of Corporate Branding  
 
Benefits of corporate branding adapted from Simon & Kotler (2003) and Hetrick & Mar-
tin (2006): 
1. Better differentiation in crowded products brand categories 
2. Consistency of an umbrella brand, prevailing over products obsolescence  
3. Clinical data can be supported by trust in the manufacturer 
4. Aiding customer purchasing decisions and promoting customer loyalty  
5. Promoting corporate culture 
 
Within branded health ingredients, companies tend to be highly specialized and level of 
diversification of their product portfolios relatively low comparing to, for example, retail 
sector. Many of the companies are SME´s, and offering expertise services, contract man-
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ufacturing or private label are not uncommon among this strategic group, making corpo-
rate branding a natural option that can offer SMEs much needed means to differentiate. 
Especially in the field of natural ingredients, generics are common – Standardized ex-
tracts, with easy global access to raw material supply – Ingredient branding may not al-
ways make sense regarding these types of products which may experience price retalia-
tion, but corporate branding can distinguish the products of a trusted branded manufac-
turer from those of a competitor. For example, French Mascuelier´s OPC extracts follow 
purely monolithic (branded house) brand architecture. With many SMEs, corporate brand 
and reputation play a bigger role than ingredient branding.   
 
Corporate brands also have important internal implications. The concept of internal 
branding has been explored in recent literature (Kornberger 2010; Hetricks & Martin 
2006). As Kornberger (2010) states: “Brands transform how we manage an organiza-
tion´s identity, how we think of its culture and how we organize innovation”. 
 
6.3. Requirements for Corporate Branding 
 
While all corporations can essentially be branded, the strength of the brand depends on 
convergence and consistency of its brand values, identity, image and brand communica-
tions. If the corporation has only one of few very distinctive products that are potential 
candidates for product or ingredient branding strategies, the allocation of resources be-
tween the corporate brand and potential product brands needs to be considered. In B2B, 
especially SMEs tend to focus on corporate branding. “Big Bioharma” like Pfizer, Wyeth, 
Merck and Astra-Zeneca have critical mass for execution of international corporate 
branding campaigns (Simon & Kotler 2003, 129), similarly food giants dealing with 
health ingredients like Cargill, nutraceutical ingredient distributor/manufacturer like 
DSM, or chemical giant BASF SE all are corporate brands “too big to fail”, while corpo-
rate branding still gives leverage also for agile SMEs, who may not have resource for 
multilevel ingredient (product) brand strategies. SMEs with innovative products should 
considered is the real value in the organisation itself, or in the actual product, because 
while corporate branding is often economic option, it may not be optimal if corporation 
itself offer little value compared to its product. 
 
6.4. Development of Corporate Brands 
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While the core brand development process follows uniform principles as suggested by 
Kotler & Keller (2012), academic literature has suggesting few specific implications. 
Corporate brand building emphasises internal processes and inclusivity. Urde (2003) dis-
cussed the importance of core values as a unifying common thread in relation with brand 
orientation: According to Urde (2003) a successful brand building process is based on 
core values. Because corporate brands are based on core values of the corporation, Kay 
(2006) suggests that socially responsible firms often create strong corporate brands.  
While these values may not be unique, their expression should be (Halttu, Tähtinen & 
Juntunen 2009). Halttu, Tähtinen & Juntunen (2009) have suggested distinctive measures 
for corporate branding in different growth stages of SME growth, starting for pre-estab-
lishment. Inception and survival are early stages where company is just beginning the 
operations and is not necessarily yet profitable, resources are scarce, and operations are 
not clearly defined. During the early phases Halttu, Tähtinen & Juntunen (2009, 51-52) 
suggest clarifying values and corporate identity where the brand is based on, and inclusive 
corporate culture. This is the critical stage where corporate brand should be formed and 
shaped. In later stages (from survival to success and maturity), the main objective is to 
maintain the brand and promote consistency for all stakeholders.  
 
 
6.5. Branding in Business-to-Business context 
 
Academic literature of Business-to-Business (B2B) branding has been limited, partially 
due to the heterogenicity of the B2B as a context (Kapferer 2008, 113). Due to the diver-
sity of sectors, markets, and activities that are grouped below, the whole concept of B2B 
Branding as a branding approach can be questioned. Because the companies operating in 
B2B basis are diverse, there are only few generic principles that apply to majority of them. 
However, there is substantial amount of evidence demonstrating the potential of B2B 
branding, while at the same time rivalry is pushing more and more component manufac-
turers (OEM´s) to pursue B2B branding strategies –  Component manufacturers face 
strong competitive pressure within the industry, but also pressure by their buyers who 
demand standardised products and components that match their own specifications, mak-
ing differentiating the product offering more difficult (Worm 2011). What is certain is 
that there are successful B2B product, ingredient, and corporate brands.  
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B2B Branding follows the same principles as B2C branding, but there are some differ-
ences: Buyers primary interact and have relationships with the company, and individual 
product brands may therefore carry less meaning. “Other than in commodities market, 
people do not buy a product but rather a supplier, with a view of durable joint develop-
ment”, as Kapferer (2008, 117) states. This requires high consistency and brand integrity, 
which companies need to actively build not only through external means, but from within 
(Worm 2011, 66-67; Webster and Keller 2004, 390). Kapferer (2008, 114) states that “in 
B2B, every ingredient forms an integrated part of the offer that the purchasing company 
makes to its own clients”. Therefore, risk management has significant role in B2B con-
texts. While B2B clients are typically perceived to base their purchasing decisions on 
rational factors (price, product specifications, lead times, etc.), research on the subject has 
demonstrated that reputation, in practice corporate brand, still plays a major role (Kap-
ferer 2008, 115). Kapferer (2008, 114) states, that price is an important consideration for 
B2B buyers, and therefore there is usually always some pressure on costs. Because B2B 
clients are driven by price considerations, mainly measurable or tangible product quali-
ties, and have limited interest to individual product brands - which leads to a trend of 
using substituting brands in industrial contexts – strong end-consumer pull must be cre-
ated in order to attract B2B buyers.  
 
 
Differentiating factors in B2B branding 
 
(1) Several individuals involved in decision-making process (prescribers) 
(2) Pressure on costs 
(3) Emphasis on corporate brand (reputation) 
(4) Emphasis on risk management 
 
Worm (2011) identified the above factor as differentiators between B2B and B2C pur-
chase and decision-making processes. B2B branding has traditionally gained little atten-
tion in biotechnology and pharmaceutical sectors. According to the Blacklett & Robins 
(2001) from Interbrand Healthcare, the restrains of B2B branding were related to supply-
driven and highly governed characteristics of these sectors. Specifications and strength 
of clinical evidence often define the strength of a product against competition. However, 
in more consumer-driven category of cosmeceuticals and nutraceuticals consumer pull 
plays a major role, often even against the clinical rationales. While the branding itself 
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follows the same principles as B2C branding, it needs to focus on prescribers and follow 
the supply chain all the way to the end-consumer and focus on de-commoditising the 
products, without forgetting the importance of the corporate brand.  
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7 SITUATIONAL ANALYSIS  
 
7.1. Microenvironment – Strategic resources and capabilities 
 
The commissioner company is relatively new, founded in 2013. Company has operated 
profitably for the first 5 years of operation. Based on SME growth stages used in theoret-
ical framework, the company is hindering between Inception and Survival. Revenue has 
remained on steady level, but there has not been new much anticipated growth during the 
past two years.  The company is serving multiple fields and has increasingly participated 
in product development as a consulting partner. The international entries are made mainly 
through distributors and agents, and through direct sales. Main export destinations are 
Japan, Korea, European countries (UK, Belgium, Germany, Sweden), and Canada.  
 
The company is currently seeking growth funding, estimated need is 350 000 € which 
will be allocated to new production facility, machinery, product development and inter-
nationalisation. The aim is to increase turnover 100 000 € in short term (by 2020) and 
double it in medium term. The project will emphasise importance of strategic planning.  
 
Table 15. SWOT-analysis 
Strengths Weaknesses 
• Unique product offering in global scale 
• Expertise and network 
• Flexibility and ability to serve different 
kind of customers 
• Ethics and sustainability 
 
• Consolidated client base 
• Limited production capacity 
• Limited resources for branding 
 
Opportunities Threats 
• Growing market 
• Increasing consumer interest towards 
health and wellbeing  
 
 
• More players in the field 
• Maturing markets 
• Continuous R&D in the field, 
new technologies emerge 
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Products Health ingredients 
Category Cosmetic ingredients, Food ingredients, Food Supplements 
Customers Category 1. Distributors 
Category 2. Manufacturers of food supplements/food products 
Main sub-segment: Natural food supplements 
Category 2. Manufacturers of cosmetic products: 
Main sub-segment: Organic / Natural Cosmetics 
Main application category: Anti-aging 
 
International en-
tries 
International sales: Distributors/agents and direct sales for in-
dividual clients 
Competition Few direct competitors; Substitutes a major threat  
Current branding Products are not branded. There is no formal strategy in foce.  
Mission statement Expert in Arctic Ingredients 
Vision statement Sustainable and natural health and wellness  
Corporate  
objectives 
Maintain the full control over the business and preserving 
family-business values. Improve and promote ethical business 
practises and CSR.  
Financial objec-
tives 
Steadily increase revenue and promote sustainable growth 
Avoid heavy investments that have no long-term viability. In-
crease revenue 100 000 € per annum in short-term (2019), 
double revenue in medium term. 
Marketing  
objectives 
Explore untapped existing marketing opportunities in domes-
tic markets and in Asia. 
Expand to Europe by finding new European distributors to 
promote stability and expand the business. 
Increase brand awareness and promote products more ac-
tively.  
Scope Distributors and manufacturers in Europe and East Asia in 
food, pharmaceutical and cosmetic sectors 
 
TABLE 16. Strategy summary 
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7.2. Macroenvironmental factors affecting branding  
 
Macroenvironmental factors analysed by using PESTEL-framework (Appendix 2.) that 
affect marketing environment are summarised in Table 17. The field is growing rapidly, 
and plant-based solutions processed by using so called mild or green technologies are 
among the fastest growing individual sectors. Biomaterials are expected to project CARG 
(compound annual rate growth) of 16% by 2020 (Marketsandmarkets, 2013). Traditional 
industry lines are becoming more and more blurred in terms of operators involved, prod-
ucts that are developed, and from regulatory perspectives: Mainstream players are enter-
ing former niche segments, nutraceutical regulation is increasingly starting to resemble 
pharmaceutical regulation and legislation is in many ways tightening. Consumers want 
data and are becoming more critical (Simon & Kotler 2003). Product and corporate brands 
need to demonstrate high level of regulatory compliance and credibility, mainly through 
verifications from third parties. The role of consumer pull as a result from DTC brand 
communications is high but restrained by health claim regulation. Bio- and plant-based 
materials are among most rabidly growing segments, and therefore branding is becoming 
more relevant than ever before.  
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TABLE 17. Summary of PESTEL-analysis (Appendix 2.) 
 
Political factors Economic factors 
• Pharmaceuticals, chemicals, food, cosmet-
ics and nutraceuticals are all highly regu-
lated. Safety is one of the main political 
concerns. 
• Regulatory bodies in EU level ECHA, 
EFSA, EMA, European Commission 
• SCCSs Opinions  
• National differences in EU, but efforts for 
uniform legislation are being made 
• Biotechnology sector subject in political 
debate (GMO, Genetechnolgy) 
 
• Market growing and maturing 
• Industry lines becoming blurred, for ex-
ample superfood trends > cosmetics, 
nutraceuticals > foods and beverages 
• CARG biomaterials 16% to 2020 
 
Social factors Technological factors 
• High-tech medicine to high-touch care – 
New era of consumerism in health care 
sector.  
• Increased focus on preventive medicine. 
• Food increasingly seen as medicine, role 
of nutrition recognised as studied. 
• In cosmetic sector, consumer interest to-
wards natural alternatives instead of syn-
thetic chemicals. 
• Fitness and wellness trends. 
• Consumers are environmentally con-
scious, increased demand in free from and 
plant-based categories. 
• DTC advertising and multilevel promotion 
needed. Brands are expected to have re-
search behind them. Health ingredients 
used as substitute for medicines, which in-
creases need for regulation.  
 
• Research plays a fundamental role in 
health ingredient field, and the sector is 
technology-intensive and very research 
oriented.  
• Technological development in the field 
has been revolutionary, marked by ge-
nomic and proteomic revolution, nano-
technology innovation, and better means 
for identifying and analysing new chemi-
cal entities, such as high-performance liq-
uid chromatography and mass spectrome-
try.   
• Role of nutrition researched extensively 
• Ethical ways to test cosmetic safety in-
stead of animal testing 
• Brands need to communicate innovation 
and simplify complex scientific messages.  
 
Environmental factors Legal factors 
• Increased interest towards sustainability  
• Environmental impact of chemical prod-
ucts 
• Consumers want to buy “natural”  
• Increasing interest towards plant-based 
products 
• New interest bodies to verify sustainabil-
ity, e.g. Fair Wild organisation 
 
• Highly regulated sectors 
• Marketing claims regulated 
• Some companies have capitalised on 
vague unscientific claims, resulting to in-
creasing consumer criticism and regula-
tion. Brands need to demonstrate high 
level of regulatory compliance.  
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7.3. Summary of in-depth interviews 
 
Supportive information for brand strategy was gathered through in-depth interviews 
among existing clients via phone, email, or meetings. Inclusion criteria was more than 
one purchase in past six months, interviews were conducted in between November 2017- 
January 2018. Eight clients from Europe, Canada and Japan participated. Following ques-
tions (Appendix 1.) were asked: 
 
Q1: Where do you get information of new ingredients or services related to them?  
Q2: Would you be able to describe the information search and purchase process in your 
company? 
Q3: Can you identify the factors your company’s purchase decisions are based on when 
you are buying active ingredients / health ingredients? 
Q4: What motivated your company to use Fingredients products / services? 
Q5: In your purchase decisions, which one you emphasize more: the supplier or the in-
gredient? Why? 
 
Clients were asked standardised open-ended questions, and answers were coded accord-
ing to which brand building instrument they represented. Brand building instruments, 
presented in the theoretical framework of these thesis were primary instruments: (1) Di-
rect experiences (2) Marketing communications (3) Price (4) Distribution. Secondary as-
sociation related instruments that affect brand image were: (1) Co-branding (2) Endorsers 
(Celebrities, opinion leaders) (3) Country-of-origin effects (4) Sponsorship. The aim was 
so gather clients’ opinions and feelings about different brand-related aspects and under-
stand them better from clients’ perspective. Whether clients focus was on individual prod-
ucts or the organisation as a whole was also a point of interest.  Clients were also asked 
about the media channels they use for obtaining information about health ingredients, and 
their purchasing process. The questions concerned B2B clients’ decision-making process 
and priorities post-purchase, and reasons why clients chose to purchase from the commis-
sioner. 
 
Clients identified several reasons why they chose to use commissioners’ services.  Find-
ings from customer in-depth interviews indicated that secondary brand building instru-
ments had an important role for existing clients. All clients mentioned one secondary 
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brand building instrument that impacted their motivation to purchase. Sustainability, ex-
pertise, origin, and natural ingredients were identified by the interviewed clients as the 
main reasons for purchasing from the commissioner. Direct experiences and marketing 
communications were also mentioned by few clients. Direct experiences were most im-
portant for domestic clients, while marketing communications were brought up by inter-
national clients.  
 
“.. I guess it is a bit of all, a combination. The origin, that the ingredients are sustainable 
and plant-based ... I think it is all important”. (Distributor, Japan) 
 
“Expertise is very important, and that the material is natural and comes from Finland” 
(Cosmetic manufacturer, Finland) 
 
Endorses are third-party quality assurance was seen as important and brought up by many 
different clients even more frequently than primary brand building instruments like price, 
distribution, or marketing. Internationally recognised certificates were mentioned by 
nearly every interviewed client.  
 
“.. We rely on third-party quality assurance rather than brands.” (Food manufacturer, 
Finland) 
 
“.. For now, this version of Ingredient X is fine, but I am thinking I would like to have all 
my products to be organic-certified in near future.” (Cosmetic Manufacturer, Canada) 
 
Another important observation was that most of the clients described whole product port-
folio or the organisation instead of individual products. This is in line with the idea from 
B2B branding theory that B2B clients primarily interact with the corporate brand instead 
of product brands.  
 
Scientific research and analysis was another theme that several clients claimed to be a 
vital part of their decision making. Some clients noted that the scientific messages are 
sometimes too complex for their end-clients and hoped manufacturers would provide 
ready-made health claims and supportive materials the distributors would be able to use.  
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“Customers are looking for different certificates, even if they do not always know what 
the certificate is about. Also, some department stores want the products with ECOCERT 
or organic certificates, so pressure comes from there. We do personal selling, and we 
must be able to explain to our staff what the benefits of using the product are. Sometimes 
it is difficult to understand for sales personnel and customers. Benefits need to be clear. 
I want to be able to explain why this ingredient is better than competitors.” (Cosmetic 
manufacturer, Japan) 
 
Online-based communication channels were identified as the most important source of 
information by majority of interviewed clients. Only one client stated that the information 
was sought from scientific publications, most of the clients said they would get infor-
mation about new ingredients from online articles and different media platforms, through 
direct experiences, and sometimes they would get interested to other products from the 
same distributor. Purchasing processes varied greatly in between organisations. For SME 
clients it was often described as informal and decisions were made only by few individ-
uals, but some distributors described standardised processed where decisions were by a 
department or by some other body that consisted of several individuals, and these deci-
sions required authorisation from higher level.  
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8 STRATEGIC OPTIONS & KEY ISSUES 
 
8.1. Main strategic options on branding level 
 
As discussed, one of the main choices regarding brand architecture is whether to imple-
ment branding in one or two levels. Should only the corporation (manufacturer) be 
branded, and products (ingredients) be regarded as generic? Should ingredients be 
branded, and manufacturer diminished, or should both corporation and its products be 
branded? Implementing two-level branding strategy requires more strategic capabilities 
and resources in terms of finances and in terms of brand management efforts. However, 
one-branding level may simply not be enough in business environment where branding 
efforts are intensifying.  
 
Scenario analysis and key issues with two branding levels: Two-branding level strat-
egy requires lots of resources and consolidation of product portfolio, because small com-
pany will have limited resources for implementing two level branding effectively. This 
would lead to a scenario where branded corporation offers few branded ingredients. Two-
branding level strategy requires, that requirements both for strong corporate brand and 
strong ingredient brands can be fulfilled, which is the case in terms of differentiation and 
uniqueness. This strategy could be beneficial in terms of internationalisation, since prod-
ucts would be standardised, well documented, and each ingredient would have clearly 
defined brand. This strategy could attract bigger clients and international distributors, 
who require high level of research, documentation, and quality assurance. The major 
trade-off would be high costs.   
 
Scenario analysis and key issues with one branding level: One branding level leads 
either to a scenario where corporation is branded and supplies range of ingredients under 
corporate brand, or to a scenario where few ingredients are branded and corporate brand 
non-existent or diminished. 
 
The main benefit of one branding level with strong corporate brand would be that the 
corporation can flexibly market tailored services and wide range of ingredients without 
increasing efforts on product branding. Socially responsible firms often create strong cor-
porate brands. Corporate branding is a key in B2B sector.  
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Developing strong corporate brand would require deeper involvement in different pro-
jects, co-branding with other corporate brands, and active participation in the field, as 
well as focus on customer service. Internationalisation of corporate SME brand may be 
difficult. Internationalisation may be sales driven, and customer relationship management 
and behavioural differentiation would play a bigger role in terms of international success. 
Corporate brand may remain local despite branding efforts in international level.  
 
Product or Ingredient Branding without corporate level would allow differentiation of 
products, targeted marketing, and this strategy might release resources for implementing 
multilevel marketing strategy (DTC-marketing). However, this strategy may not be well 
in line with principles of Business-to-Business branding and utilise expertise and flexi-
bility that the commissioner would be able to provide for its clients. Ingredient branding 
level would clarify where the products stand in terms of competition. It is also a riskier 
strategy, because it reduces agility to switching from one products to another in case a 
product is underperforming – A very plausible scenario in a field that is driven by novelty. 
Clients require extensive amount of technical and clinical data of the products, and prod-
ucts clearly fulfil basic criteria for Ingredient Branding: They are highly differentiated, 
central for the functional performance of finished product, final products would benefit 
for co-branding, and finished products are typically complex. The source is an important 
factor in terms of unique value proposition (UVP), which suggests that one-level branding 
strategy may not be optimal in terms of differentiation and in terms of establishing unique 
positioning.  
 
 
8.2. Main strategic options on brand architecture 
 
Brand architecture is linked with the choice of branding levels. Organisation would ben-
efit for two branding levels, as concluded above, but management of two-level brand 
strategy requires lots of strategic capabilities and resources, which are typically scarce in 
SMEs. The structure of the brand architecture is therefore highly strategic choice, which 
will guide the allocation of these resources. Strategic options are visualised in Figure 18.  
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FIGURE 18. Visualisation of brand architecture options 
 
Brand architecture should represent value distribution, as discussed in theoretical frame-
work of this thesis. Therefore, the organisation needs to map where the value is located. 
According to insights from existing clients obtained during the in-depth interviews, most 
of the clients spoke about the organisation instead of describing features of an individual 
ingredient, which indicates that clients primarily interact with corporate brand. This idea 
is supported by the B2B branding theory and would guide towards corporation-centric 
architecture.  
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8.3. Main strategic options on brand positioning 
 
In theoretical framework of this thesis positioning scenario mapping was suggested by 
Kapferer (2008) as part of brand development process. Eleven key aspects were listen on 
theoretical framework, they were: (1) compatibility (how compatible said positioning is 
with the overall business strategy?), (2) consumer motivation (does it motivate buyers to 
purchase?), (3) market size (potential market size when positioning is achieved?), (4) 
credibility (is the positioning credible, does it represent the product or corporation? Can 
it be trusted?), (5) competitive aspects (who are the competitors if this positioning is 
achieved, and can organisation compete against them?), (6) financial resources (does the 
organisation have enough financial resources to achieve this positioning?), (7) distinc-
tiveness (does positioning support differentiation?) (8) sustainable competitive advantage 
(does this positioning provide sustainable competitive advantage?) (9) exit in case of fail-
ure (can the organisation exit the positioning if it not working?) (10) price premium (does 
the positioning justify price premiums?) and finally, (11) growth potential (are there 
growth opportunities if this positioning is chosen?). Scenario analysis was conducted by 
using these eleven aspects and analysing them in three different branding scenarios: Po-
sitioning as unbranded supplier, positioning as multi-segment branded supplier, and po-
sitioning as branded supplier of highly differentiated branded products.  
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Scenario 1. Company remains as manufacturer of generic products (No branding or only 
minimal corporate branding). 
 
Compatibility Not compatible with overall business strategy (differentiation). 
Does not support core strengths (SWOT). 
Consumer motivation Consumers motivated by lower price compared to branded of-
ferings, alternative to branded products “non-branded” strategy.  
Market size Limited, because European manufacturers cannot compete with 
Asian manufacturers in terms of costs.  
Credibility Built case-by-case basis with each customer. Does not  
Competitive aspects Competition with Asian low-cost manufacturers, while material 
quality clearly differs. 
Financial resources  Minimal resources needed in terms of branding.  
Distinctiveness Products not differentiated by marketing or branding, distinc-
tiveness on functional qualities. Distinctiveness communicated 
separately to each client. Company not differentiated or mini-
mally differentiated.   
Sustainable competitive ad-
vantage 
No, unless low-cost business strategy is used.  
 
Possibility to exit in case of failure  Little investments made, exit is easy.  
Price premium  Position does not justify premium price. 
Growth potential  Limited. 
 
TABLE 19. Scenario 1 – Non-branding strategy 
 
Summary: This scenario describes current situation. Orientation is in existing consumer 
relationship. Brands discreet, reputation-based. Products are differentiated, but marketed 
as generic, which puts them in the same line with lower-quality products. Strategy is does 
not provide sustainable competitive advantage, because it is relative easy to imitate.   
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Scenario 2. Branded supplier of generic health ingredients. 
 
Compatibility Compatible with business strategy. Basis for corporate 
brand exists (logo, COO, reputation built in first five years 
of operation, visuals, etc.). Capitalises on core strengths 
and in line with strategic resources and competences. 
Consumer motivation Consumers motivated by price and corporate brand (repu-
tation, service, experiences with the company, word-of-
mouth).  
Market size Market focus (Most important markets), allows local re-
sponsiveness in terms of products when they are not 
branded. 
Credibility Favourable source effects (COO), expertise, and special-
ised processed justify positioning. 
Competitive aspects Differentiated products compete may be placed in same 
line with low-cost options due to lack of product brands. 
Financial resources  Not as resource intensive as two-level branding strategy, 
low risk of investment going to waste in case of individual 
product fails.  
 
Distinctiveness Distinctive corporate brand. Undistinguished products. 
Distinctiveness does not necessarily flow through whole 
value chain to end-consumers or finished product manu-
facturers, since distributors interact with corporate brand.  
 
Sustainable competitive advantage Based on corporate brand.  
Possibility to exit in case of failure  Allows flexibility in terms of products portfolio, minimal 
investments on product brands = Easy to add new prod-
ucts under corporate umbrella and discontinue with unsuc-
cessful products.  
 
Price premium  Corporate brand justifies price premiums, but product 
price premiums not on same level with category leading 
ingredient.  
 
Growth potential  SME may not be able to capitalise corporate brand in in-
ternational scale.  
  
 
TABLE 20.  Scenario 2 – Positioned as trusted supplier of generics 
 
Summary: Branding the corporation but not product allows services for several seg-
ments. In international scale, this strategy allows local responsiveness. It allows flexibil-
ity in terms of product portfolio, justified price premiums to some extent, and is compat-
ible to overall business strategy. However, the main challenges are that creation of truly 
international brand may be difficult, and the consumer pull -effect not achieved. The strat-
egy works well with service concept, which makes it a suitable option for the commis-
sioner.  
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Scenario 3. Branded supplier of branded ingredients for targeted segments. 
 
 
 
 
 
 
 
 
 
 
 
Compatibility Compatible with business strategy (differentiation). Basis for 
corporate brand exists (logo, COO, reputation built in first 
five years of operation, visuals, etc.). Ingredients fulfil basic 
criteria for ingredient branding. Ingredients are differenti-
ated. Positioning capitalises on core strengths and in line 
with strategic resources and competences. 
 
Consumer motivation Consumers motivated by corporate brand (Source effects, 
COO, service, expertise) and ingredient brands.  
 
Market size Global reach, globally standardised branded product (brand-
ing requires resources, little resources available for local re-
posiveness) 
 
Credibility Favourable source effects (COO), expertise, and specialised 
processed justify positioning. “Natural” and “Green” prod-
uct alternatives.  
 
Competitive aspects Differentiation from generic / low-cost manufacturers and 
products.  
 
Financial resources for strategy im-
plementation 
While this positioning is very resource intensive, it protects 
investments made in terms of product quality.  
 
Distinctiveness of the strategy Distinctiveness in level of each product, distinctive against 
other suppliers. 
 
Sustainable competitive advantage Strategy offers sustainable competitive advantage against 
competitors in each product category. 
 
Possibility to exit in case of failure  Investments on product brands mean consolidation and 
heavier specialisation are required, since exiting becomes 
more difficult.  
 
Justification of price premium  Justifies price premiums and promotes price elasticity.  
 
Growth potential  Positioning aims at tapping core opportunities and growth in 
the field.  
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TABLE 21. Scenario 3. – Branded niche supplier 
 
Summary: Corporation has distinctive corporate brand, positioned to serve certain 
segments. Ingredients are branded, and brands are targeted for niche-audiences, each 
product will need to have individual brand positioning. When resources are scarce 
and developing brands binds resources, company may need to consolidate product 
offerings. Higher investments mean higher risks. This positioning is highly sophisti-
cated and would work best with innovation driven company with heavy R&D invest-
ments.  
 
 
 
 
8.4. Main strategic options on brand identity 
 
Corporate brand identity is formed by corporate culture, corporate behaviour, corporate 
internal communications and corporate design, according to theoretical framework of this 
thesis, and should be based on the core values of the company. Corporate culture is fam-
ily-business oriented and emphasises long-term orientation and partnerships, which rep-
resent the core values and goals. According to the theory, SMEs in early growth stages 
often have very lean structure, and corporate culture and internal communications are 
informal and formed in day-to-day operations of a firm, which may lead to inconsistency 
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in terms of brand identity. Structured reflection of identity is important at this early stage, 
because the company can adopt brand-oriented thinking early on, and drive consistency 
over the corporate brand. Figure 22 is a mind-map of the core elements of corporate self-
identity.  
 
FIGURE 22. Identity mind map based on self-image. 
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9 BRAND MANAGEMENT PLAN 
 
 
9.1. Branding levels 
 
In the inception or survival phases of SMEs organisational development process the com-
missioner should focus on corporate branding based on research findings and situational 
analysis. In practice this may translate to one branding level. This is the brand that B2B 
clients and other stakeholders in B2B sector primarily interact with, it resonates favoura-
ble source-effects and can cover agile, wide, and rapidly changing product portfolio. This 
enables flexibility in terms of products. Figure 23 represents branding levels and brand 
architecture as an evolving construct. Phase 1. represents short-term goals for branding 
strategy, where there is only one branding level and main objective is to create a strong 
corporate brand. Phase 2. represents next level where organisation is in a phase where it 
has strategic resources and capabilities for implementing tow-level brand strategy, and 
where strong corporate brand has already been established.  
 
 
 
FIGURE 23. Branding levels as evolutionary process  
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Branding levels and brand architecture are evolving and dynamic structures. Second 
branding level can be implemented when organisation grows, after the situation is reas-
sessed and product portfolio refined. Products fulfil basic requirements for ingredient 
branding, but two-level brand architecture is a heavy construct for a small operator. Two-
levelled structure would optimally support differentiation and thus the overall business 
strategy. Second level becomes easy to build after corporate brand is able to work as a 
real endorsement for product (ingredient) brands.  
 
Second branding level (Ingredient brands) may require portfolio refining and consolida-
tion towards the most promising core products. Trade-offs may be necessary. Ingredient 
products that are potential candidates for branding can be selected based on growth in 
their respective category, current sales value, sales potential, uniqueness, and potential 
positioning among number of factors.  
 
 
9.2. Brand Architecture 
 
Corporate Masterbrand is suggested as a brand architecture type based on situational anal-
ysis as well as theoretical and empirical findings. Corporate brand should be strongly 
connected to its geographic origin (favourable COO-effects) and built on core values of 
the business. Focus should be on driving consistency, creating clear corporate identity 
and developing brand-oriented corporate culture. Commissioner can offer R&D and tai-
lored services for clients. Strategy allows local responsiveness in international markets. 
Figure 24 represents proposed brand architecture.  
 
 
 
 
FIGURE 24. Proposed brand architecture model 
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9.3. Positioning  
 
Based on scenario analysis, organisation should focus branding efforts towards corporate 
brand. Company has already pre-established a very niche position in terms of the products 
and services. Positioning is, in the end, formed through customer perception, so the com-
pany can only select a target positioning. Position target was selected through a two-
staged process which was described in theoretical framework of this thesis. The first stage 
is the selection of competitive set against which brand is compared. Since the organisation 
has already established niche-positioning, set was selected from within this positioning. 
Looking at the direct competitors in service and product level, they differ firstly from 
where their services and products are located in the value chain – While all organisations 
supply ingredients, some are positioned towards private label – services or have own fin-
ished consumer brand along with their ingredient business.  
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FIGURE 25. Position mapping among industry peers and competitors 
 
 
 
A competitive set was selected among companies which work with same products. Most 
of these operators, like the commissioner, cater several industry sectors (medical, cosmet-
ics, foods, nutraceuticals), but some are more focused towards certain sectors. There are 
several companies working with same bio-materials and services as the commissioner. 
Some operators have positioned more towards the end-product and may be even manu-
facturing consumer products along with extracts. These operators have vertically inte-
grated business models. Another axis (graph 25) is level of R&D and services, which 
many operators in technologically oriented and complex field provide along with bio-
materials or extracts. This axis can also be thought as axis of flexible vs. standardised 
products. At the other end there are purely service businesses who a set of field-specific 
B2B consulting and R&D services, and in the other end there are suppliers who are purely 
focused on their own production and materials. In between there are operators who pro-
vide both materials and services related to their field of expertise.  
 
The second stage of positioning is indication of difference or raison d´étre in comparison 
to other brands. Corporate brand is differentiated from other similar manufacturers in its 
service-approach and flexibility in terms of processes, expertise, analytical approach, and 
service models. The expertise and in the other hand sort of a pilot R&D plant format 
should be emphasised, these form raison d´étre of the corporate brand. There are corpo-
rate brands which are purely R&D and consulting firms offering very specialized market-
ing-oriented services, so the corporate brand needs to be able to offer more practical and 
holistic approach compared to these brands.  
 
Product differentiation is based on sustainability and origin. This differentiates the ingre-
dients clearly from synthetic chemical, and creates a positioning where CSR plays a cen-
tral role. Products differ from vast amount of bio-based materials through their origin. 
Product brands should be further differentiated from other bio-based ingredients by clin-
ical and science-based approach. 
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TABLE 26. Evolving international strategy and positioning  
 
 
9.4. Identity 
 
Brand identity should be based on core values. Based on in-depth interviews, most of the 
customers identified expertise and sustainability as the most important reasons for their 
purchase decision, and these were also identified by the commissioner as the core values 
(Mind map of Figure 22). Because the corporation is R&D-oriented, customer relation-
ships should be driven by customers business growth. These are among the core values 
which can be used as foundations for value-based corporate brand. 
 
69  
 
 
 
 
 
FIGURE 27. Corporate brand identity prism, adapted from Kapferer (2008). 
 
The commissioner has kept apart from hype and trend-driven business approach which is 
typical in B2C health and wellness sector. Because the company provides different ex-
pertise services related to documentation, safety, and regulations, compliance and science 
based-approach are important for business integrity.  
 
 
 
9.5. Brand communications 
 
The company currently has a corporate website and is listed in few industry channels. 
Advertising is mainly done through corporate website. Direct sales, sales promotions and 
personal selling has not been used proactively. Corporation has participated in some 
events in domestic market and visited international events. After the brand management 
strategy implementation, brand communication mix should be more proactive and brand-
oriented. Online-based channels are emphasised because of their cost-effectiveness, in-
ternational coverage and ability to reach B2B clients that are smaller and do not neces-
sarily operate in international scale themselves.  
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BRAND COMMUNICA-
TION MIX 
Current situation After the strategy implementation 
Advertising Company web-site is the most 
important advertising channel. 
Listed in few supplier catalogues 
online. 
  
Company website remains an im-
portant channel, but industry channels 
and platforms will be taken to more 
active use, and advertising done 
mainly through them.  
Sales promotion No sales promotions. Sales promotions in forms of samples 
of new products which may be inter-
esting for existing clients. 
Events & Experiences Limited participation. Active participation, event participa-
tion also in international level in core 
market areas.  
PR & Publicity Reactive, few inquiries re-
sponded every now and then. 
Proactive, corporate brand driven ap-
proach.  
 
Direct marketing  No direct marketing. Direct marketing for existing clients 
in forms of information updates and 
content marketing.  
 
Interactive marketing LinkedIn and Facebook as inter-
active social media channels that 
are used for brief news updates. 
 
LinkedIn and Facebook as interactive 
marketing channels and main commu-
nication channels for brand and con-
tent marketing.  
Personal selling No personal selling.  Personal selling for intermediates in 
regular intervals (follow-up meetings 
and product development discus-
sions). 
 
 
TABLE 28. Brand Communication Mix 
 
Corporate website remains as one of the cornerstones for brand building after the strategy 
implementation and should communicate values and brand identity. Based on client in-
sights from in-depth interviews, online-based brand communications do have an im-
portant role in customers decision making. Clients opinions suggested online-based chan-
nels may be the first customer touchpoints in the purchasing process. Therefore, online-
based marketing is emphasised in Brand Communications Mix. Online-based communi-
cation provides several cost-efficient media channels, including industry platforms, 
which offer readily-targeted audiences (Brandedingredient.com, SpecialChem, Nu-
traingredients etc). This is important for an SME with little resources for data collection 
and online segmentation. Online-based communications should be monitored – This is 
easy since there are several tools available. When listings are done, channels should be 
compared and once there is enough data visibility increased in channels which generate 
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the highest number of online leads. Most of the industry channels provide different visi-
bility options or ready-made marketing packages which can be utilised. 
 
Another objective is to increase presence in the field by increasing participation. This 
means active event and seminar participation, which from the brand management per-
spective communicates expertise and helps in building brand reputation. Participating as 
an expert or a speaker could be seen as a form of content marketing. This will also help 
in building network and creating a positive brand image.  
 
One of the brand communication instruments that could provide real value for the com-
missioner is content marketing. Several industry channels support content marketing ap-
proach, and it can be implemented as part of social media marketing. Other manufacturers 
provide, for example, formulating tutorials, marketing tutorials, and distribute third-party 
publications like blog posts. 
 
 
9.6. Tactical decisions & Marketing Mix 
 
Main tactical decisions are increasing presence in most important industry channels, im-
plementing brand-oriented thinking throughout the operations and starting to both proac-
tively promote the products, as well as collecting and analysing feedback from the strate-
gic business environment. Product portfolio should be consolidated and products more 
standardised to ensure consistent quality. Stronger online-based presence should be built, 
especially in industry channels. Promotion should be proactive instead of reactive, and 
direct sales and personal sales implemented as parts of routine marketing processes. 
Online-based promotion should extend to industry channels of all key segments, and con-
tent marketing approach should be implemented for new leads. These channels should be 
monitored for their efficacy and coverage.  
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Tactical decisions 
 
 
1.   Products 
 
I.           Corporate logo should be attached to all products. 
 
II.          Product portfolio should be assessed and then consolidated 
 
III.         Products should be standardised for consistent 
quality. IV.        Products should be third-party quality 
verified. 
V.          Quality signs (certifications) should be attached to products. 
 
 
 
2.   Price 
 
I. Pricing tactics should not entirely be cost-based and should be 
more reactive to market prices. 
3. Place 
 
I. 
 
 
Stronger presence in industry channels. 
 II. Brand needs to visible in expert channels. 
 III. Internationalization both directly and by increasing co-operation with key 
 
distributors. 
 IV. 
 
V. 
Mapping co-operative internationalization schemes. 
 
Increasing co-operation in local business networks. 
 
 
4.   Promotion 
 
I. Marketing materials should be updated, each product should have 
a consolidated, consistent information package. 
II.        Active sales approach instead of passive reactions. 
 
III.     Online-based promotions and advertising should be updated to in-
crease visibility. Key channels should be mapped and then evalu-
ated. Channels should be monitored, and easy-to-use analytics im-
plemented. 
IV.      Content and social media marketing not as news updates, instead a 
structured individual marketing plans for interactive media. 
V. Direct sales and personal sales (meeting clients, discussing, analys-
ing and informing) should be routine marketing operations. 
VI.      Implementation of marketing analytics especially in digital envi-
ronments. 
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5.   Physical evidence 
 
I. Physical evidence needs to project high-quality and sus-
tainability.  
II. Physical evidence needs to present the brand. 
III.       Biodegradable packaging alternatives  
IV.      Brand symbols attached to packaging. 
V.        All documents should contain logo and visuals. 
 
 
 
6.   People 
 
I.           Everyone needs to commit to brand values. 
 
II.          Employees should be developed in their field of expertise. 
 
 
 
 
7.   Process 
 
I.           Service process should be more agile and faster. 
II.          Information readily available clients in clear form to spare time 
spend on customer service. 
III.         Project management tools implemented for consulting and 
R&D pro- jects. 
IV.         Feedback and references gathered after purchase or completed 
project, analysed, and process developed. 
 
 
 
Marketing Mix is summarised below in Table 31, where both current marketing mix and 
marketing mix after the tactical decisions have been implemented are compared. Table 
29 summarises how brand management strategy for 2018 will transform company’s mar-
keting mix and what are the most important changes after above described tactical deci-
sions are implemented. 
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MARKETING MIX  Current situation After strategy implementation 
Product Not branded, wide portfolio. 
Based on own production and dis-
tribution. 
Branded, narrower portfolio, consoli-
dated to core products. Based on own 
production. 
 
Price Cost-based pricing.  Cost-based pricing.  
Place Dependent on online environ-
ment. Manufacturing sites not ac-
cessible. 
  
Dependent on online environment. 
More transparent manufacturing. 
Presence in trade-fairs and events.  
Promotion Little promotion; Mainly online-
based. Limited amount of product 
information openly available. Cli-
ents are provided samples and 
product data, which is mainly 
technical. Little sales promotion.  
 
Promotion is targeted for manu-
facturers, no promotion for end-
consumers or other links in supply 
chain.  
Each individual product brand has 
own information package where all 
data is combined, and brands have 
own online-based promotion sites 
which are connected with the corpo-
rate site. More information is openly 
available.  
 
Content marketing, participation in 
research, and networking events 
should be used for promotion corpo-
rate brand.  
 
Inclusion of direct sales to clients. 
Inclusion of multilevel brand com-
munications where applicable. Cor-
porate branding for clients, ingredient 
branding for whole chain. 
 
Physical Evidence Product samples.  
Industrial packaging. Printed, no 
visual brand signs attached. 
Product samples packed in biode-
gradable branded package. Increasing 
biodegradable packaging alternatives. 
Brand visuals attached. 
 
People  Skilled and academic workforce, 
but no personal branding. People 
behind the company are not ac-
tively promoted. Roles are some-
times unclear.  
 
 
Highly skilled and academic work-
force, “experts”. Certifications and 
additional education should be acces-
sible and encouraged. CBBE mind-
set. Personal branding to support cor-
porate brand. Clear roles.  
 
Process Product information fragmented, 
composed based on technical 
standards.   
 
Process is sometimes slow. Pro-
ject management tools not in ac-
tive use.  
Brand information consolidated to 
help sales. Combined based on tech-
nical standard and customer needs. 
Clinical information and research is 
made easily available and linked with 
marketing claims clients may be able 
to use.  
 
Ready-made sample and brochure 
sets ease sales, sample delivery 
should be prompt and fast, within 
few business days. 
 
Project management should be ac-
tively implemented in R&D projects. 
 
 
TABLE 29. Marketing Mix 
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9.7. Summary 
 
The commissioner is applying for growth funding for term 2018-2019, the initial project 
involves 350 000 € of total funding for new investments and internationalisation (pro- 
cessing unit, machinery, product development, international channel development). The 
brand plan aims at supporting this project and the growth targets (100 000 € turnover 
increase in short-term, at least one new full-time position created in terms of work force, 
doubling sales revenue in medium term). 
 
Brand plan emphasises corporate brand, which has a central position in Business-to-busi- 
ness arena. Corporates identity should be based on its core values: Sustainability, sincer-
ity, and competence. The brand should be able to capitalise on favourable COO-effects. 
Corporate brand should be positioned as a specialised niche supplier: The greenest alter- 
native, an R&D service provider and industry expert. In operational level, emphasis is on 
increasing presence – Both in online-based environments and in industry channels. An- 
other important aim is to cultivate trust. This should be done through third-party verifica-
tion (certificates, other quality-signs), through testimonials and references, and by keep-
ing production chain and operations transparent. 
 
Annually, corporate branding expenses and marketing expenses are estimated to be close 
to 7% of total turnover (median 2014-2016), but this includes trade-show participation 
and some non-recurring costs associated with strategy implementation. However, there 
are internationalisation schemes and collaborative internationalisation projects to support 
internationalisation of SMEs. Prioritisation over of quality assurance -related costs are 
suggested over heavy IPR Management strategy. 
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10 CONCLUSIONS 
 
Situational analysis, supportive empirical findings and theory stressed the importance of 
a strong corporate brand.  Two-levelled brand architecture would be optimal for highly 
differentiated organisation which manufactures highly differentiated products, but SMEs 
like the commissioner may need to focus on their corporate brand. Focusing on corporate 
brand helps maintaining branding costs at tolerable level, management of multiple brands 
does not employ unreasonable amount of resources, and risks associated with investing 
on single product brand can be avoided. Effective ingredient branding would require mul-
tilevel approach to marketing, since the consumer pull effect is in the heart of this strat-
egy. When organization develops and grows, more globally integrated strategies can be 
implemented, and multilevel marketing may become more realistic strategic choice. 
 
Brand policies and strategies should be aligned with organizational structure and overall 
business and corporate strategies. Strategies should promote integrity and consistency of 
brands, especially in Business-to-Business sector, which emphasises relationships and 
corporate brands. Based on all available evidence, business-to-business companies can 
still benefit from diverse branding strategies, and there is not necessarily a single strategic 
solution that would fit to all – Strategy needs to be adjusted for each growth stage, it needs 
to be a dynamic and evolving structure that is always questioned, reassessed, and adapted 
to its changing environment. Companies should adopt brand-oriented thinking early on 
and focus on driving consistency and continuously analysing their environment, brand, 
positioning and customer and stakeholder perceptions. 
 
Brands are based on value, and branding decisions are guided by the location of the real 
customer value – Whether it is the product, its component, the manufacturer or the seller. 
Well-managed brands generate brand equity and help in building sustainable competitive 
advantage: They extend product life cycles, lower price elasticity, allow price premiums, 
increase customer loyalty, and built corporate reputation. Brands can neither be empty 
and separate from the tangible aspects of the products. They are highly strategic assets, 
and even though they have become integrated part of both D2C and B2B sales arenas 
both in local and international levels, brand management strategies should be based on 
critical analysis and assessment.  
 
77  
 
 
 
Collecting and analysing feedback is essential to further brand development. Constant 
analysis helps keeping the corporate brand relevant and up-to-date in changing business 
environment. The commissioner needs to develop a monitoring system for analysing and 
collecting feedback on brand awareness and perceptions. Conducting situational analysis 
on frequent intervals helps in detecting and predicting changes in operational environ-
ment and enables development of agile brand strategies. Because this thesis was entirely 
focused on developing brand plan and a brand management strategy for the commis-
sioner, brand monitoring systems were not included within the scope of this work despite 
their importance. Brand and marketing research is recommended in regular intervals. 
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11 DISCUSSION  
 
The biopharma and health ingredient sectors are at turning point, and companies need to 
rethink of their business models. Branding may be a part of the solution, and manufactur-
ers have diverse strategies to choose from. Brand policies and strategies should be aligned 
with organizational structure and overall business and corporate strategies. Strategies 
should promote integrity and consistency of brands, especially in Business-to-Business 
sector, which emphasises relationships and corporate brands.  
 
Intellectual property management has a central role in the field, and the complex issues 
related to it are interesting prospects for future research. Brands may not work without 
other quality signs in health ingredient field, and quality signs should be used as brand 
building instruments. Third-party verified signs of quality have central role for SMEs in 
reputation building. The brands are not all powerful, they are just a set of signs which 
signal uniqueness: Without real tangible value and meaningful difference brands will fail.  
 
There is still only limited amount of scientific publications of B2B branding and Ingredi-
ent Branding. Further studies are needed to fully understand systematics of branding in 
these fields. Another question is whether these are valid starting points for research, and 
whether a versatile and heterogenous group of OEMs can be or should be generalised. 
Clients in in-depth interviews described their internal purchase processes very differently 
based on mainly the size of their organisation. SMEs and MNEs may have very different 
systematics, and brand development and branding strategy may be something very dif-
ferent in highly innovative start-ups compared to corporate giants. While fundamental 
principles of branding remain uniform no matter the sector or whether the brand is B2B 
or B2C, processes and outcomes may vary.  
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APPENDICES   
Appendix. 1.  In-depth interview questions 
                        Page 1 (1) 
 
In-depth interviews were conducted by using semi-structured questions, in which follow-
ing questions were used:  
 
Q1: Where do you get information of new ingredients or services related to them?  
Q2: Would you be able to describe the information search and purchase process in your 
company? 
Q3: Can you identify the factors your company’s purchase decisions are based on when 
you are buying active ingredients / health ingredients? 
Q4: What motivated your company to use Fingredients products / services? 
Q5: In your purchase decisions, which one you emphasize more: the supplier or the in-
gredient? Why? 
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Appendix 2. PESTEL-analysis 
Page 1 (6) 
 
PESTEL or PESTLE is a framework used for the analysis of different macro-environ-
mental factors, used in strategic analysis for scanning external environment. PESTEL 
analysis covers political, economic, social, technological, environmental and legal factors 
that create the external environment where organisation operates in. The analysis con-
ducted here is focused on branding perspective.   
 
Political factors affecting marketing macroenvironment in European Union 
 
Regulation has a huge impact on the market – Pharmaceuticals, chemicals, food, cosmet-
ics and nutraceuticals are all highly regulated. Safety is one of the main political concerns. 
Main regulatory bodies within EU are: 
 
ECHA – European Chemicals Agency 
ESFA – European Food Safety Authority 
European Commissions Cosmetic Directive – Cosmetic Ingredients 
EMA – European Medicines Agency 
 
In European Union, when preparing policy and proposals related to consumer safety, 
health and the environment, the Commission relies on independent Scientific Committees 
to provide it with sound scientific advice and draw its attention to new and emerging 
problems. There are two important committees: 
•  Scientific Committee on Consumer Safety (SCCS) 
• Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) 
 
EFSA European Food Safety Authority is another body giving scientific advice for the 
European Commission, the European Parliament and EU Member States. Political land-
scape is not uniform at the moment, and national authorities have lots of power in enforc-
ing the regulations.  
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Economic factors affecting marketing macroenvironment in European Union 
 
The biomaterials market is projected to reach USD 149.17 Billion by 2021 from USD 
70.90 Billion in 2016, at a CAGR of 16.0%, according to Marketsandmarkets, (2016) 
market research. The market is segmented into four main regions in this market research: 
North America, Europea, Asia Pacific and Rest of the World, out of this North America 
accounting for the largest share but Asia Pacific projecting strongest growth. Health in-
gredient markets are expected to grow to 101.32 Billion USD by 2022 (Marketsandmar-
kets 2016). The plant segment accounted for the largest share in the health ingredients 
market, in terms of value, in 2016, and Europe was the most lucrative region while Asia-
Pacific protected the highest CARG in 2017. Plant-based ingredient sector has grown 
massively in the past few years. This has intensified the competition in the field and 
strategized branding. Companies now need to carefully consider their positioning and 
differentiate their offerings.  
 
Social factors affecting macroenvironment in European Union 
 
Social factors highly influence the demand (consumer pull) of health ingredients, among 
the following factors. 
 
1. How strong is the consumer pull (demand) for the products?  
2. What societal factors create/restrain pulling effects 
3. How sensitive consumers are for branded offerings? 
4. What societal factors affect brand image and brand perceptions? 
 
Information revolution, globalization and internet technology, rise of consumer activism 
and pharmaceutical and cosmetic industries failures to acknowledge and address some of 
the side-effects and ethical issues have created a base of critical, informed, and active 
consumers. Some patient-organisations have been known for aggressively lobbying in 
biopharma sector for the favour of innovative health ingredients, while cosmetic and food 
ingredient consumers are active advocates and spread messages in favour of natural, sus-
tainable, ethical and environmentally friendly solutions, creating driving forces for brands 
that are able to cultivate confidence and trust among the buyers and communicate safety,  
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efficacy, and sustainability. Simon & Kotler (2003) propose paradigm shift from high-
tech medicine to high-touch care – New era of consumerism in health care sector.  
 
While marketing communications used to be a communication process between active 
sender (manufacturer or seller) and passive receiver (the customer), this approach to mar-
keting communications have become obsolete as consumers have become powerful 
agents in forming brand perceptions (Percy & Elliot 2005). These social trends question  
traditional DTC-approach, and Simon & Kotler (2003) proposed already ten years ago 
inclusion of quasi-professional level in communications targeted for consumers with dif-
ferent knowledge levels. Markets are becoming fragmented, as we have entered in an era 
of choice economy (Kapferer 2008, 149): Consumers are highly involved in decisions 
concerning their own health. Informed consumers are sceptical, and often want reassur-
ance from other quality signs besides the brand, in natural ingredient sector for example 
there is an increasing demand from free from- and clean label products with quality cer-
tificates: In a survey of  1,300 consumers across Europe, North America and Asia-Pacific 
by Ingredient Communications  -Agency, 76 percent of respondents said they would be 
more likely to buy a product that contained ingredients they recognized and trusted, and 
over half of the respondents was ready to spend more on a product which ingredients they 
were familiar with (Bizzozero 2017). As a conclusion, societal changes in macroenviron-
ment have intensified consumer pull effect and emphasize the importance of DTC com-
munications.  
 
 
Technological factors affecting macroenvironment in European Union 
 
Research plays a fundamental role in health ingredient field, and the sector is technology-
intensive and very research oriented. Technological development in the field has been 
revolutionary, marked by genomic and proteomic revolution, nanotechnology innovation, 
and better means for identifying and analysing new chemical entities, such as high-per-
formance liquid chromatography and mass spectrometry.  These analysing techniques 
have fed ethnopharmacological research together, which, together with better understand-
ing of the dangers of synthetic chemicals, has created a strong body of research around  
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natural ingredients and substances, which in turn has led to expansion of botanical ingre-
dients market. At the same time, better understanding of function of human bodies and 
role of nutrition is pushing continuous innovation in the field of food and nutrition sci-
ence. In the last century, probiotics for example, were relatively unknown (Probiotics are 
“live micro-organisms that when administered in adequate amounts confer a health ben-
efit on the host”, according to World Health Organization 2001). Over the past decade, 
research on human microbiome and benefits of probiotics have soared, and so has the 
market growth, raising probiotics the fastest growing ingredient category in 2017 (mar-
ketsandmarkets 2016). While the research started from yogurt and fermented milk prod-
ucts, nowadays technology allows manufacturing and storage of micro-organism strains, 
which can be incorporated into food or cosmetics, or used as drugs. There are several 
branded probiotics in the market.  
 
 
FIGURE 1. Favourable scientific and regulatory environment feeds innovation  
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Environmental factors affecting marketing macroenvironment in the EU 
 
Natural and plant-based ingredients are rapidly growing market segments driven by en-
vironmental concerns. Humans have increasingly started to recognise how environment 
and health are linked with each other, and how consumption patterns affect the environ-
ment (Notarnicola et al. 2017). Driven by these concerns and overspill from the food 
industry, plant-based alternatives have risen as a health ingredient trend in recent years, 
aligning with increasing number of consumers choosing a vegetarian and flexitarian life-
style and turning towards greener options.   
 
Legal factors affecting marketing macroenvironment in the EU 
 
While new product and technologies emerge in accelerating speed, regulation follows 
closely behind. Health ingredient field is highly regulated by national and international 
legislation. Legislation regulates marketing from the following perspectives: 
 
1. What products can be marketed?  
2. What applications the products can be marketed for?  
3. What documentation or marketing approvals are required?  
4. What marketing claims can be made? 
 
Health ingredients may fall under cosmetic, medicine and food safety regulations. Legis-
lation differs by country. In European Union, the main regulatory bodies for health ingre-
dients are EFSA (European Food Safety Authority) and EMA (European Medicines 
Agency), while Cosmetic Ingredients are regulated by European Commissions Cosmetic 
Directives. In USA, the corresponding body is FDA (Food and Drug Administration). 
Among with European legislative framework, national law is applied. Legislative frame-
work will depend on with category the health ingredient falls, as the legislation differs 
based on whether the products is classified as cosmetic ingredient, food ingredient or 
pharmaceutical ingredient, while botanical ingredients can in theory fall to all of these 
categories and may be considered under different categories in different member states 
due to divergent national legislation, until uniform European legislation is enforced. 
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Some EU member states have already started to work for uniform legislative framework, 
Italy, France and Belgium for example have cooperatively created BELFRIT-project de-
signed to provide a common approach to regulate use of botanicals in food supplements.  
 
The General Food Law created a European food safety system in which responsibility for 
risk assessment (science) and for risk management (policy) are kept separate. EFSA is 
responsible for the former area, risk management, and has a duty to communicate its sci-
entific findings to the public. EFSA regulates health claims, based on regulation (EC) no 
1924/2006 of the European parliament and of the council of 20 December 2006 on nutri-
tion and health claims made on foods. A health claim is any statement on labels, adver-
tising or other marketing products that health benefits can result from consuming a given 
food, for instance that a food can help reinforce the body’s natural defences or enhance 
learning ability. Not limited only to B2C, the health claim regulation concerns also B2B 
manufacturers (ESFA, 2016). Health ingredients cannot be market without authorised 
claims, so health claim regulation has significant effect both on markets and marketing 
communications. Companies can apply for health claims, but approval requires substan-
tial amount of scientific research supporting the claim, and the process is costly for SMEs. 
While there may be a limited body of research supporting certain health claims for the 
ingredient, unless authorised, the marketing claims cannot be made in B2C or B2B mar-
keting communication, which directly affects different brand identity components and 
consumer perceptions of the products. According to Bech-Larsen & Scholderer (2007), 
the fact that the European markets for functional foods generally are less developed, com-
pared to the US and the Japanese markets, has often been attributed to a restrictive and 
inconsistent health claim legislation in and between the European countries. EFSA also 
regulates novel foods, which require marketing authorisation. Novel food legislation af-
fects several biotechnology and health ingredient products intended as functional foods 
or supplements, and especially highly innovative companies may face challenges regard-
ing novel food regulation, and it practically works as a trade barrier.   
 
